TWI802545B

TWI802545B - Compositions comprising bacterial strains

Info

Publication number: TWI802545B
Application number: TW106123394A
Authority: TW
Inventors: 多納迪耶安妮克柏納利爾; 羅琳克魯茲; 克蘿伊阿布齊
Original assignee: 英商４Ｄ製藥有限公司
Priority date: 2016-07-13
Filing date: 2017-07-12
Publication date: 2023-05-21
Also published as: IL272982B; US20180200307A1; TW201805011A; SI3313422T1; SG10201913602XA; KR102060388B1; SG11201810571RA; PT3313421T; DK3313421T3; CO2019000135A2; KR102045372B1; MD3313421T2; ES2719837T3; PE20190451A1; CY1121766T1; MA42278A; PE20190207A1; US20210338744A1; CA3028903A1; US20180369292A1

Abstract

The invention provides compositions comprising one or more bacterial strains for treating or preventing diarrhea and/or constipation.

Description

Compositions comprising bacterial strains

本發明係包含自哺乳動物消化道分離之細菌菌株之組合物及該等組合物在治療疾病中之用途的領域。The present invention is in the field of compositions comprising bacterial strains isolated from the digestive tract of mammals and the use of such compositions in the treatment of disease.

在子宮內時人類腸子被認為是無菌的，但出生之後，其立即暴露於各式母體及環境微生物。此後，發生微生物定殖及演替之動態期，其由諸如遞送模式、環境、飲食及宿主基因型等因素影響，所有因素皆影響腸微生物區系之組成，尤其係在生命早期。隨後，微生物區系較為穩定且變成成人樣狀態[1]。人類腸微生物區系含有1500種以上不同種系型，主要種系型係具有豐富濃度之兩種主要細菌門(division、phyla )擬桿菌門(Bacteroidetes)及硬壁菌門(Firmicutes) [2-3]。源自人類腸之細菌定殖之成功共生關係已產生眾多種代謝、結構、保護及其他有益功能。經定殖腸之強化之代謝活性可確保原本不消化飲食組分會發生降解且釋放提供用於宿主之重要營養物來源及其他健康益處之副產物。類似地，腸微生物區系之免疫學重要性已充分認可且例示於具有在引入共生細菌後在功能上重構之受損免疫系統之無菌動物中[4-6]。微生物區系組成之顯著變化已展現於胃腸道病症(例如發炎性腸病(IBD))中。舉例而言，梭菌(Clostridium ) XIVa簇及梭菌XI簇(普拉梭菌(F. prausnitzii ))細菌在IBD患者中之濃度有所降低，而大腸桿菌(E. coli )之數量有所增加，從而表明共生體及致病共棲菌譜在腸內之平衡發生移動[7-11]。在認識到某些細菌菌株對動物腸具有之潛在正效應後，已提出各種菌株來用於治療各種疾病(例如參見[12-15])。已提出諸多菌株(主要包括乳桿菌(Lactobacillus )及雙歧桿菌屬(Bifidobacterium )菌株)來用於治療各種腸病(綜述可參見[16])。亦提出布勞特氏菌(Blautia )屬菌株來用於調節IBS患者中之消化生態系統之微生物平衡(WO 01/85187)。然而，並未充分表徵不同細菌菌株與不同疾病之間之關係及特定細菌菌株對腸及在全身性濃度下及對任一特定類型疾病之確切效應。需要表徵腸細菌之潛在效應，從而可研發使用腸細菌之新療法。 US 2010/0247489闡述使用礦物質營養物來治療消化病症。US‘789提出視情況亦使用諸多不同細菌屬來預防眾多種腹部症狀，但並未建立任一細菌與任一疾病或症狀之關聯性。 WO 2016/086206表明，可使用梭菌(Clostridiale)目細菌來治療或預防各種病狀，但並未建立任一細菌與任一疾病或症狀之關聯性。 WO 2012/142605提出，可使用微生物組合來治療諸多不同疾病。WO’605提出大量可採用之可能細菌物種，但在WO’605中並無關於所提出任一細菌物種可如何用於治療所提出任一疾病之教示內容。 WO 02/07741提出使用來自梭菌類之各種細菌來治療胃腸道病症，但並未建立任一細菌與任一疾病或症狀之關聯性。WO 2016/086209提出使用梭菌目中之大量可能細菌來降低促發炎性細胞介素之分泌及/或增加抗發炎性細胞介素之分泌，但並無關於所提出任一細菌物種可如何用於治療所提出任一疾病之教示內容。The human intestine is considered sterile while in utero, but immediately after birth it is exposed to a variety of maternal and environmental microorganisms. Thereafter, a dynamic period of microbial colonization and succession occurs, influenced by factors such as mode of delivery, environment, diet, and host genotype, all of which affect the composition of the gut microbiota, especially early in life. Subsequently, the microbiota becomes more stable and becomes adult-like [1]. The human intestinal microflora contains more than 1500 different phylotypes, and the main phylotypes have rich concentrations of two major bacterial phyla (division, phyla ) Bacteroidetes and Firmicutes [2- 3]. Successful symbiotic relationships derived from bacterial colonization of the human gut have yielded a wide variety of metabolic, structural, protective, and other beneficial functions. The enhanced metabolic activity of the colonized intestine ensures that otherwise indigestible dietary components are degraded and release by-products that provide a source of vital nutrients and other health benefits for the host. Similarly, the immunological importance of the gut microflora is well recognized and exemplified in germ-free animals with compromised immune systems that are functionally reconstituted upon introduction of commensal bacteria [4-6]. Significant changes in microflora composition have been demonstrated in gastrointestinal disorders such as inflammatory bowel disease (IBD). For example, Clostridium ( Clostridium ) cluster XIVa and Clostridium cluster XI ( F. prausnitzii ) bacteria had decreased concentrations in IBD patients, while E. coli increased, indicating that the balance of symbionts and pathogenic commensal bacteria in the intestinal tract has shifted [7-11]. Following the recognition of the potential positive effects certain bacterial strains have on the animal gut, various strains have been proposed for the treatment of various diseases (see eg [12-15]). Many strains (mainly including Lactobacillus and Bifidobacterium strains) have been proposed for the treatment of various intestinal diseases (for a review, see [16]). Strains of the genus Blautia have also been proposed for regulating the microbial balance of the digestive ecosystem in IBS patients (WO 01/85187). However, the relationship between different bacterial strains and different diseases and the exact effect of a particular bacterial strain on the gut and at systemic concentrations and on any particular type of disease is not well characterized. There is a need to characterize the potential effects of gut bacteria so that new therapies using gut bacteria can be developed. US 2010/0247489 describes the use of mineral nutrients for the treatment of digestive disorders. US'789 proposes the use of many different bacterial genera as appropriate to prevent a wide variety of abdominal symptoms, but does not establish a correlation between any one bacterium and any one disease or symptom. WO 2016/086206 shows that bacteria of the order Clostridiale can be used to treat or prevent various conditions, but does not establish a link between any bacterium and any disease or symptom. WO 2012/142605 proposes that combinations of microorganisms can be used to treat many different diseases. WO'605 proposes a large number of possible bacterial species that could be employed, but there is no teaching in WO'605 as to how any of the proposed bacterial species could be used to treat any of the proposed diseases. WO 02/07741 proposes the use of various bacteria from the Clostridia genus for the treatment of gastrointestinal disorders, but does not establish a link between any bacterium and any disease or condition. WO 2016/086209 proposes the use of a large number of possible bacteria from the order Clostridium to reduce the secretion of pro-inflammatory cytokines and/or increase the secretion of anti-inflammatory cytokines, but is silent on how any of the proposed bacterial species can be used Instructions on treating any disease presented.

發明者已研發用於治療及預防腹瀉及/或便秘之新療法。特定而言，發明者已鑑別出，來自布勞特氏菌屬之細菌菌株可有效用於減輕腹瀉及/或便秘。如實例中所闡述，經口投與包含氫營養型布勞特氏菌(Blautia hydrogenotrophica )之組合物可減輕刺激性腸症候群(IBS)患者之腹瀉及/或便秘。因此，在第一實施例中，本發明提供包含用於治療或預防腹瀉及/或便秘之方法中之布勞特氏菌屬細菌菌株之組合物。在較佳實施例中，本發明提供包含用於治療或預防經診斷患有克羅恩氏病(Crohn's disease)、潰瘍性結腸炎或更佳地IBS之個體之腹瀉及/或便秘之方法中之布勞特氏菌屬細菌菌株的組合物。在一些實施例中，經診斷患有IBS之個體患有具有腹瀉及便秘之IBS。在一些實施例中，經診斷患有IBS之個體患有具有腹瀉但無便秘或具有僅少量便秘之IBS。在一些實施例中，經診斷患有IBS之個體患有具有便秘但無腹瀉或具有僅少量腹瀉之IBS。在本發明之較佳實施例中，組合物中之細菌菌株係氫營養型布勞特氏菌。亦可使用密切相關之菌株，例如具有與氫營養型布勞特氏菌細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列之細菌菌株。較佳地，細菌菌株具有與SEQ ID NO:5至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。最佳地，組合物中之細菌菌株係以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株。在本發明之其他實施例中，組合物中之細菌菌株係糞堆布勞特氏菌(Blautia stercoris )。亦可使用密切相關之菌株，例如具有與糞堆布勞特氏菌細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列之細菌菌株。較佳地，細菌菌株具有與SEQ ID NO:1或3至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地，序列一致性係針對SEQ ID NO:3。較佳地，用於本發明中之細菌菌株具有由SEQ ID NO:3代表之16s rRNA序列。在本發明之其他實施例中，組合物中之細菌菌株係魏克拉-布勞特氏菌(Blautia wexlerae )。亦可使用密切相關之菌株，例如具有與魏克拉-布勞特氏菌細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列之細菌菌株。較佳地，細菌菌株具有與SEQ ID NO:2或4至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地，序列一致性係針對SEQ ID NO:4。較佳地，用於本發明中之細菌菌株具有由SEQ ID NO:4代表之16s rRNA序列。在某些實施例中，本發明組合物係用於經口投與。經口投與本發明菌株可有效治療腹瀉及/或便秘。同樣，經口投與便利於患者及從業人員且容許遞送至腸及/或部分或完全定殖於腸中。在某些實施例中，本發明組合物包含一或多種醫藥上可接受之賦形劑或載劑。在某些實施例中，本發明組合物包含已凍乾之細菌菌株。凍乾係用於製備容許遞送細菌之穩定組合物之有效及便利技術，且在實例中展示可提供有效組合物。在某些實施例中，本發明提供包含如上文所闡述之組合物之食品。在某些實施例中，本發明提供包含如上文所闡述之組合物之疫苗組合物。另外，本發明提供治療或預防腹瀉及/或便秘之方法，其包含投與包含布勞特氏菌屬細菌菌株之組合物。在較佳實施例中，本發明提供包含布勞特氏菌屬細菌菌株之組合物，該組合物係用於治療或預防與腸桿菌科(Enterobacteriaceae )感染(例如大腸桿菌感染)有關之疾病之方法中。在某些實施例中，本發明組合物係用於治療或預防腹瀉、胃腸炎、尿路感染或新生兒腦膜炎。在其他較佳實施例中，本發明組合物係用於降低胃腸道中之腸桿菌科濃度、較佳地大腸桿菌濃度，治療或預防IBS、克羅恩氏病、潰瘍性結腸炎、功能消化不良、腹瀉、胃腸炎、尿路感染或新生兒腦膜炎。在尤佳實施例中，本發明組合物係用於治療或預防與腸桿菌科感染(例如大腸桿菌感染)有關之腹瀉之方法中，或用於降低胃腸道中之腸桿菌科濃度、較佳地大腸桿菌濃度，用於治療或預防腹瀉。The inventors have developed new treatments for the treatment and prevention of diarrhea and/or constipation. In particular, the inventors have identified that bacterial strains from the genus Blautia are effective for alleviating diarrhea and/or constipation. As illustrated in the Examples, oral administration of a composition comprising Blautia hydrogenotrophica reduces diarrhea and/or constipation in patients with irritable bowel syndrome (IBS). Thus, in a first embodiment, the present invention provides a composition comprising a bacterial strain of the genus Blautia for use in a method of treating or preventing diarrhea and/or constipation. In a preferred embodiment, the present invention provides a method comprising use in the treatment or prevention of diarrhea and/or constipation in an individual diagnosed with Crohn's disease, ulcerative colitis or more preferably IBS Composition of bacterial strains of the genus Blautia. In some embodiments, the individual diagnosed with IBS has IBS with diarrhea and constipation. In some embodiments, the individual diagnosed with IBS has IBS with diarrhea and no constipation or with only mild constipation. In some embodiments, the individual diagnosed with IBS has IBS with constipation but no diarrhea or with only a small amount of diarrhea. In a preferred embodiment of the present invention, the bacterial strain in the composition is hydrogenotrophic Blautia spp. Closely related strains may also be used, for example having a 16s rRNA that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a hydrogenotrophic Blautia bacterial strain sequence of bacterial strains. Preferably, the bacterial strain has a 16s rRNA sequence at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. Optimally, the bacterial strain in the composition is a hydrogenotrophic strain of Blautia spp. deposited under accession number DSM 10507/14294. In other embodiments of the present invention, the bacterial strain in the composition is Blautia stercoris . Closely related strains may also be used, for example having a 16s rRNA sequence at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of B. faecalis of bacterial strains. Preferably, the bacterial strain has a 16s rRNA sequence that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 1 or 3. Preferably, the sequence identity is to SEQ ID NO:3. Preferably, the bacterial strain used in the present invention has a 16s rRNA sequence represented by SEQ ID NO:3. In other embodiments of the present invention, the bacterial strain in the composition is Blautia wexlerae . Closely related strains may also be used, for example having a 16s rRNA that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to the 16s rRNA sequence of a bacterial strain of Brautia weiclae-Broutia sequence of bacterial strains. Preferably, the bacterial strain has a 16s rRNA sequence at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 2 or 4. Preferably, the sequence identity is to SEQ ID NO:4. Preferably, the bacterial strain used in the present invention has a 16s rRNA sequence represented by SEQ ID NO:4. In certain embodiments, compositions of the invention are for oral administration. Oral administration of the strain of the present invention can effectively treat diarrhea and/or constipation. Likewise, oral administration is convenient for the patient and practitioner and allows delivery to the intestine and/or partial or complete colonization in the intestine. In certain embodiments, compositions of the invention comprise one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, compositions of the invention comprise bacterial strains that have been lyophilized. Lyophilization is an efficient and convenient technique for preparing stable compositions that allow for the delivery of bacteria and was shown in the Examples to provide effective compositions. In certain embodiments, the present invention provides a food product comprising a composition as set forth above. In certain embodiments, the invention provides a vaccine composition comprising a composition as set forth above. In addition, the present invention provides a method of treating or preventing diarrhea and/or constipation comprising administering a composition comprising a bacterial strain of the genus Blautia. In a preferred embodiment, the present invention provides a composition comprising bacterial strains of the genus Blautia for use in the treatment or prevention of diseases associated with Enterobacteriaceae ( Enterobacteriaceae ) infections (such as Escherichia coli infections) method. In certain embodiments, compositions of the invention are used to treat or prevent diarrhea, gastroenteritis, urinary tract infection, or neonatal meningitis. In other preferred embodiments, the composition of the present invention is used to reduce the concentration of Enterobacteriaceae, preferably Escherichia coli, in the gastrointestinal tract for the treatment or prevention of IBS, Crohn's disease, ulcerative colitis, functional dyspepsia , diarrhea, gastroenteritis, urinary tract infection, or neonatal meningitis. In a particularly preferred embodiment, the composition of the present invention is used in a method for treating or preventing diarrhea associated with an Enterobacteriaceae infection (such as an Escherichia coli infection), or for reducing the concentration of Enterobacteriaceae in the gastrointestinal tract, preferably Escherichia coli concentration for the treatment or prevention of diarrhea.

細菌菌株本發明組合物包含布勞特氏菌屬細菌菌株。實例證實，此屬細菌可用於治療或預防腹瀉及/或便秘。較佳細菌菌株係物種氫營養型布勞特氏菌、糞堆布勞特氏菌及魏克拉-布勞特氏菌。用於本發明中之其他較佳細菌菌株係延長布勞特氏菌(Blautia producta )、球形布勞特氏菌(Blautia coccoides )及漢遜-布勞特氏菌(Blautia hansenii )。用於本發明中之布勞特氏菌菌株之實例包括氫營養型布勞特氏菌、糞堆布勞特氏菌、糞便布勞特氏菌(B. faecis )、球形布勞特氏菌、格魯拉瑟-布勞特氏菌(B. glucerasea )、漢遜-布勞特氏菌、魯替-布勞特氏菌(B. luti )、延長布勞特氏菌、史恩基-布勞特氏菌(B. schinkii )及魏克拉-布勞特氏菌。布勞特氏菌屬係可為球形或卵形之革蘭氏反應陽性(Gram-reaction-positive)、非運動性細菌且皆係產生乙酸作為葡萄糖發酵之主要端產物之絕對厭氧菌[17]。布勞特氏菌可自人類腸分離，但延長布勞特氏菌係自敗血病試樣所分離。氫營養型布勞特氏菌(先前稱為氫營養型瘤胃球菌(Ruminococcus hydrogenotrophicus ))已自哺乳動物腸分離出，其嚴格厭氧，且將H₂ /CO₂ 代謝成可對人類營養及健康較為重要之乙酸鹽。氫營養型布勞特氏菌之菌株類型係S5a33 = DSM 10507 = JCM 14656。氫營養型布勞特氏菌菌株S5a36之16S rRNA基因序列之基因庫登錄號為X95624.1 (在本文中揭示為SEQ ID NO:5)。此實例性氫營養型布勞特氏菌菌株闡述於[17]及[18]中。S5a33菌株及S5a36菌株對應於自健康個體之糞便試樣所分離菌株之兩種亞純系。其展示相同形態、生理學及代謝且相同16S rRNA序列。因此，在一些實施例中，用於本發明中之氫營養型布勞特氏菌具有SEQ ID NO:5之16S rRNA序列。以登錄號DSM 10507亦及以登錄號DSM 14294寄存之氫營養型布勞特氏菌細菌測試於實例中且亦在本文中稱為菌株BH。由Deutsche Sammlung von Mikroorganismen [德國微生物保藏中心(German Microorganism Collection)] (Mascheroder Weg 1b, 38124 Braunschweig，德國)將菌株BH在1996年1月以登錄號DSM 10507寄存為「氫營養型瘤胃球菌」且亦在2001年5月10日以登錄號DSM 14294寄存為「S5a33」。寄存者為INRA Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122 Saint Genès Champanelle，法國。寄存所有權已藉由轉讓轉移給4D Pharma Plc。糞堆布勞特氏菌菌株GAM6-1^T 之16S rRNA基因序列之基因庫登錄號為HM626177 (在本文中揭示為SEQ ID NO:1)。實例性糞堆布勞特氏菌菌株闡述於[19]中。魏克拉-布勞特氏菌之菌株類型係WAL 14507 = ATCC BAA-1564 = DSM 19850 [17]。魏克拉-布勞特氏菌菌株WAL 14507 T之16S rRNA基因序列之基因庫登錄號為EF036467 (在本文中揭示為SEQ ID NO:2)。此實例性魏克拉-布勞特氏菌菌株闡述於[17]中。較佳糞堆布勞特氏菌菌株係以登錄號NCIMB 42381寄存之菌株，其亦在本文中稱為菌株830。830菌株之16S rRNA序列提供於SEQ ID NO:3中。菌株830經國際寄存授權機構NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA，蘇格蘭)由GT Biologics Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS，蘇格蘭)於2015年3月12日寄存為「糞堆布勞特氏菌830」且分配登錄號NCIMB 42381。GT Biologics Ltd.隨後改名為4D Pharma Research Limited。較佳魏克拉-布勞特氏菌菌株係以登錄號NCIMB 42486寄存之菌株，其亦在本文中稱為菌株MRX008。MRX008菌株之16S rRNA序列提供於SEQ ID NO:4中。菌株MRX008經國際寄存授權機構NCIMB, Ltd. (Ferguson Building, Aberdeen, AB21 9YA，蘇格蘭)由4D Pharma Research Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS，蘇格蘭)於2015年11月16日寄存為「布勞特氏菌/ 瘤胃球菌MRx0008 」且分配登錄號NCIMB 42486。與實例中所測試菌株密切相關之細菌菌株亦預計可有效治療或預防腹瀉及/或便秘。在某些實施例中，用於本發明中之細菌菌株具有與氫營養型布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致的16s rRNA序列。較佳地，用於本發明中之細菌菌株具有與SEQ ID NO:5至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。在某些實施例中，用於本發明中之細菌菌株具有與糞堆布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致的16s rRNA序列。較佳地，用於本發明中之細菌菌株具有與SEQ ID NO:1或SEQ ID NO:3至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地，序列一致性係針對SEQ ID NO:3。較佳地，用於本發明中之細菌菌株具有由SEQ ID NO:3代表之16s rRNA序列。在某些實施例中，用於本發明中之細菌菌株具有與魏克拉-布勞特氏菌之細菌菌株之16s rRNA序列至少95%、96%、97%、98%、99%、99.5%或99.9%一致的16s rRNA序列。較佳地，用於本發明中之細菌菌株具有與SEQ ID NO:2或SEQ ID NO:4至少95%、96%、97%、98%、99%、99.5%或99.9%一致之16s rRNA序列。較佳地，序列一致性係針對SEQ ID NO:4。較佳地，用於本發明中之細菌菌株具有由SEQ ID NO:4代表之16s rRNA序列。作為以登錄號DSM 10507/14294寄存之細菌生物型或以登錄號NCIMB 42381及NCIMB 42486寄存之細菌生物型係之細菌菌株亦預計可有效治療或預防腹瀉及/或便秘。生物型係具有相同或極類似生理學及生物化學特性之密切相關菌株。作為以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌生物型且適用於本發明中之菌株可藉由測序以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌的其他核苷酸序列來進行鑑別。舉例而言，可測序實質上全基因體且用於本發明中之生物型菌株可在至少80%之其全基因體中(例如在至少85%、90%、95%或99%中，或在其全基因體中)具有至少95%、96%、97%、98%、99%、99.5%或99.9%之序列一致性。舉例而言，在一些實施例中，生物型菌株在至少98%之其基因體中具有至少98%序列一致性或在99%之其基因體中具有至少99%序列一致性。用於所鑑別生物型菌株中之其他適宜序列可包括hsp60或重複序列(例如BOX、ERIC、(GTG)₅ 或REP或[20])。生物型菌株可具有與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之相應序列具有至少95%、96%、97%、98%、99%、99.5%或99.9%序列一致性之序列。在一些實施例中，生物型菌株具有與寄存為DSM 10507/14294之氫營養型布勞特氏菌菌株之相應序列具有至少97%、98%、99%、99.5%或99.9%序列一致性之序列且包含與SEQ ID NO:5至少99%一致(例如至少99.5%或至少99.9%一致)的16S rRNA序列。在一些實施例中，生物型菌株具有與寄存為DSM 10507/14294之氫營養型布勞特氏菌菌株之相應序列具有至少97%、98%、99%、99.5%或99.9%序列一致性之序列且具有SEQ ID NO:5的16S rRNA序列。或者，作為以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌生物型且適用於本發明中之菌株可藉由使用寄存登錄號DSM 10507/14294、寄存登錄號NCIMB 42381或寄存登錄號NCIMB 42486及限制片段分析及/或PCR分析(例如藉由使用螢光擴增片段長度多型性(FAFLP)及重複DNA元件(rep)-PCR指紋技術或蛋白質描述或部分16S或23s rDNA測序)來進行鑑別。在較佳實施例中，可使用該等技術來鑑別其他氫營養型布勞特氏菌、糞堆布勞特氏菌或魏克拉-布勞特氏菌菌株。在某些實施例中，作為以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌生物型且適用於本發明中之菌株係在藉由擴增核糖體DNA限制分析(ARDRA)分析時(例如在使用Sau3AI限制酶時) (關於實例性方法及導則，例如參見[21])以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌提供相同模式的菌株。或者，將生物型菌株鑑別為與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌具有相同碳水化合物發酵模式之菌株。可使用任一適當方法或策略(包括實例中所闡述之分析)來鑑別可用於本發明之組合物及方法中之其他布勞特氏菌菌株(例如以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌之生物型)。舉例而言，可藉由培養細菌且投與大鼠以在擴張分析中進行測試來鑑別用於本發明中之菌株。特定而言，與以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之細菌具有類似生長模式、代謝類型及/或表面抗原之細菌菌株可用於本發明中。有用菌株將與DSM 10507/14294、NCIMB 42381或NCIMB 42486菌株具有相當之微生物區系調節活性。特定而言，生物型菌株對腹瀉及/或便秘誘發與實例中所展示效應相當之效應，該等效應可藉由使用實例中所闡述之培養及投與方案進行鑑別。本發明之尤佳菌株係以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株。此係實例中所測試且展示有效治療疾病之實例性BH菌株。因此，本發明提供用於療法中、尤其用於本文所闡述疾病之以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株或其衍生物之細胞(例如經分離細胞)。以登錄號DSM 10507/14294、NCIMB 42381或NCIMB 42486寄存之菌株之衍生物可為子菌株(子代)或來自原始菌株之菌株培養物(亞選殖)。可修飾(例如在基因層面上)本發明菌株之衍生物且並不去除生物活性。特定而言，本發明之衍生菌株具有治療活性。衍生菌株與原始DSM 10507/14294、NCIMB 42381或NCIMB 42486菌株具有相當之微生物區系調節活性。特定而言，衍生菌株對腹瀉及/或便秘誘發與實例中所展示效應相當之效應，該等效應可藉由使用實例中所闡述之培養及投與方案進行鑑別。DSM 10507/14294菌株之衍生物通常係DSM 10507/14294菌株之生物型。NCIMB 42381菌株之衍生物通常係NCIMB 42381菌株之生物型。NCIMB 42486菌株之衍生物通常係NCIMB 42486菌株之生物型。所提及以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株之細胞涵蓋任何與以登錄號DSM 10507/14294寄存之菌株具有相同安全性及治療效能特性的細胞，且該等細胞由本發明涵蓋。所提及以登錄號NCIMB 42381寄存之糞堆布勞特氏菌菌株之細胞涵蓋任何與以登錄號NCIMB 42381寄存之菌株具有相同安全性及治療效能特性的細胞，且該等細胞由本發明涵蓋。所提及以登錄號NCIMB 42486寄存之魏克拉-布勞特氏菌菌株之細胞涵蓋任何與以登錄號NCIMB 42486寄存之菌株具有相同安全性及治療效能特性的細胞，且該等細胞由本發明涵蓋。在較佳實施例中，本發明組合物中之細菌菌株係可生長發育的且能夠部分地或完全定殖於腸中。治療用途在較佳實施例中，本發明組合物係用於治療腹瀉及/或便秘。在一些實施例中，組合物係用於治療患有腹瀉及便秘之患者。在一些實施例中，組合物係用於治療患有腹瀉但未患有便秘之患者。在一些實施例中，組合物係用於治療患有便秘但未患有腹瀉之患者。儘管患者通常展現腹瀉或便秘，但個別患者可在不同時間展現兩種病狀。患有IBS及/或腸發炎性疾病之患者通常會展現腹瀉及/或便秘。因此，本發明提供用於治療經診斷患有或懷疑患有IBS或腸發炎性疾病之患者之本發明組合物。舉例而言，IBS患者可經歷交替循環之腹瀉及便秘或IBS患者可被描述為患有腹瀉之IBS患者或患有便秘之IBS患者。在一些實施例中，可使用本發明組合物來治療IBS患者、具有腹瀉之IBS患者或具有便秘之IBS患者。舉例而言，在一些實施例中，經診斷患有IBS之個體患有具有腹瀉及便秘二者之IBS。在一些實施例中，經診斷患有IBS之個體患有具有腹瀉但無便秘或具有僅少量便秘之IBS。在一些實施例中，經診斷患有IBS之個體患有具有便秘但無腹瀉或具有僅少量腹瀉之IBS。在一些實施例中，發炎性疾病係小腸、結腸或直腸之疾病。腹瀉係克羅恩氏病及潰瘍性結腸炎之症狀。因此，可使用本發明組合物來治療克羅恩氏病或潰瘍性結腸炎患者。如實例中所證實，本發明細菌組合物可有效用於減輕腹瀉及/或便秘。在較佳實施例中，本發明組合物係應用於治療或預防與克羅恩氏病、潰瘍性結腸炎或更佳地IBS有關之腹瀉及/或便秘。在較佳實施例中，本發明組合物係用於治療或預防經診斷患有克羅恩氏病、潰瘍性結腸炎或更佳地IBS之個體之腹瀉及/或便秘。在較佳實施例中，本發明組合物係用於治療或預防在治療克羅恩氏病、潰瘍性結腸炎或更佳地IBS中之腹瀉及/或便秘。在一些實施例中，除腹瀉及/或便秘外，患者患有腹痛及/或氣脹病。在該等實施例中，患者可患有該等病狀中之兩者、三者或所有四者之任一組合。舉例而言，患者可患有腹瀉、便秘、腹痛及氣脹病；腹瀉、便秘及腹痛；腹瀉、便秘及氣脹病；腹瀉、腹痛及/或氣脹病，無便秘；便秘、腹痛及/或氣脹病，無腹瀉。在某些實施例中，組合物可呈細菌培養物形式。在一些實施例中，組合物可較佳係凍乾物。在一些實施例中，本發明組合物係用於治療相對於健康個體在呼吸中具有增加之氫濃度之個體之腹瀉及/或便秘。在一些實施例中，本發明組合物係用於降低患有腹瀉及/或便秘之個體在呼吸中之氫濃度。個體較佳係診斷為患有IBS及/或腸發炎性疾病之個體。在一些實施例中，發炎性疾病係小腸、結腸或直腸之疾病。在一些實施例中，個體已經診斷患有克羅恩氏病、潰瘍性結腸炎或更佳地IBS，例如本文所闡述之一類IBS。不受限於理論，據推測，經增加之氫濃度係源自腸發炎之潛在機制。實例展示，使用本發明組合物進行治療可降低在氫呼吸測試中所檢測之氫濃度。因此，較佳地使用氫呼吸測試(hydrogen breath test)來評價氫濃度。氫呼吸測試在業內已眾所周知且由此熟習此項技術者知曉如何實施此一測試。在一些實施例中，向患者投與乳酮糖以作為測試受質。氫呼吸測試亦係用於監測使用本發明組合物進行治療或預防之有效性或可能有效性之有用工具。舉例而言，在藉由本發明組合物治療或預防後在個體呼吸中所檢測之氫之濃度降低可指示，治療具有治療或預防效應。因此，在一些實施例中，本發明之方法及用途進一步包含在使用本發明組合物治療或預防期間及/或之後監測個體呼吸中之氫濃度且由此評價治療或預防之有效性或可能有效性。舉例而言，可監測氫濃度一或多次(例如1、2、3、4或大於4次)，例如視需要包括在治療之前、在治療開始、在治療期間、在治療結束及/或在治療後。在一些實施例中，將在投藥期(在此期間向個體投與組合物)結束及/或之後個體呼吸中之氫濃度與投藥期開始及/或之前之濃度進行比較，且濃度降低指示治療或預防之有效性或可能有效性。舉例而言，在投藥期為16天之實施例中，可期望在第1天及第16天或(例如)在第1天、第2天、第15天及第16天進行量測。在一些實施例中，獲取多個量測且獲得彼等量測之平均值(例如第1天及第2天之平均值及第15天及第16天之平均值)。在一些實施例中，氫濃度Cmax降低至少40 ppm指示，治療或預防有效或可能有效。在一些實施例中，僅量測一次個體呼吸中之氫濃度(例如在治療結束或之後)，且在發現濃度處於或接近預定濃度時可指示治療或預防可能有效。氫呼吸測試係標準分析且由此業內已知預定濃度。在某些實施例中，本發明組合物係用於預防正接受或已接受或準備接受(例如在同一天稍後、第二天或在2、3、4、5、6、7、10、14或21天內)抗生素治療或正患有或已患有細菌胃腸炎之個體之腹瀉及/或便秘。抗生素治療及細菌胃腸炎與可先於腹瀉及/或便秘且可藉由本發明組合物預防之腸微生物區系變化有關。本發明組合物可與抗生素治療同時、分開或依序投與。舉例而言，本發明組合物可與抗生素治療同時投與。在較佳實施例中，使用本發明組合物進行治療可減輕腹瀉及/或便秘。預防或預防腹瀉及/或便秘可係指(例如)緩解症狀嚴重程度或降低加重頻率或對患者具有問題之觸發事件範圍。在某些實施例中，本發明組合物係用於治療或預防與腸桿菌科感染(例如大腸桿菌感染)有關之疾病。在某些實施例中，本發明組合物係用於治療或預防腹瀉、胃腸炎、尿路感染或新生兒腦膜炎。在該等實施例中，腸桿菌科可為病原性菌株。在某些實施例中，本發明組合物係用於治療或預防與增加之腸桿菌科(例如大腸桿菌)濃度有關之疾病。在某些實施例中，本發明組合物係用於治療或預防腹瀉、胃腸炎、尿路感染或新生兒腦膜炎。在該等實施例中，腸桿菌科可為共生或非病原性菌株。在較佳實施例中，本發明組合物係用於降低胃腸道中之腸桿菌科濃度、較佳地大腸桿菌濃度，治療或預防與增加之腸桿菌科濃度有關之疾病(例如IBS、克羅恩氏病、潰瘍性結腸炎、功能消化不良、腹瀉、胃腸炎、尿路感染或新生兒腦膜炎)。腸桿菌科及尤其大腸桿菌已知潛在地觸發或已知加重克羅恩氏病及潰瘍性結腸炎[22-24]，因此本發明組合物在實例中所展示之效應可有益於治療該等病狀。在某些實施例中，本發明組合物係用於藉由降低胃腸道中之腸桿菌科濃度來治療或預防IBS、克羅恩氏病、潰瘍性結腸炎、功能消化不良、腹瀉、胃腸炎、尿路感染或新生兒腦膜炎。投與模式較佳地，擬將本發明組合物投與胃腸道以使得能夠將本發明細菌菌株遞送至及/或部分或完全定殖於腸中。通常，經口投與本發明組合物，但其可經直腸、經鼻內或經由經頰或舌下途徑來投與。在某些實施例中，可以發泡體、噴霧或凝膠形式來投與本發明組合物。在某些實施例中，本發明組合物可以栓劑(例如直腸栓劑)形式投與，例如以可可樹油(可可油)、合成硬脂肪(例如舒芙賽(suppocire)、維特普斯爾(witepsol))、甘油-明膠、聚乙二醇或肥皂甘油組合物之形式。在某些實施例中，經由管(例如鼻胃管、口胃管、胃管、空腸造口術管(J管)、經皮內鏡胃造瘺術(PEG)管)或孔(例如進入胃、空腸之胸壁孔及其他適宜進入孔)將本發明組合物投與胃腸道。本發明組合物可投與一次，或其可作為治療方案之一部分依序投與。在某些實施例中，每天投與本發明組合物。實例證實，投與提供治療腹瀉及/或便秘之成功定殖及臨床益處。在某些實施例中，規則性(例如每天、每兩天或每週)投與本發明組合物延長時間段，例如至少一週、兩週、一個月、兩個月、6個月或一年。實例證實，BH投與不會永久性定殖於腸中，因此規則投與延長時間段可提供較大治療益處。在一些實施例中，投與本發明組合物7天、14天、16天、21天或28天或不超過7天、14天、16天、21天或28天。舉例而言，在一些實施例中，投與本發明組合物16天。在本發明之某些實施例中，本發明治療伴有患者腸微生物區系之評價。若並未達成本發明菌株之遞送及/或部分或完全定殖以致未觀察到效能，則可重複治療，或若達成成功遞送及/或部分或完全定殖且觀察到效能，則可停止治療。在某些實施例中，可將本發明組合物投與懷孕動物(例如哺乳動物，例如人類)以預防發生於子宮內及/或出生後兒童中之腹瀉及/或便秘。可將本發明組合物投與已經診斷患有腹瀉及/或便秘或與腹瀉及/或便秘有關之疾病或病狀或已鑑別為處於腹瀉及/或便秘之風險下之患者。亦可作為預防性措施來投與組合物以預防在健康患者中發生腹瀉及/或便秘。可將本發明組合物投與鑑別為具有異常腸微生物區系之患者。舉例而言，患者可具有減少之布勞特氏菌及尤其氫營養型布勞特氏菌、糞堆布勞特氏菌或魏克拉-布勞特氏菌之定殖或不存在該定殖。可以食品(例如營養補充品)形式來投與本發明組合物。通常，本發明組合物係用於治療人類，但其可用於治療包括單胃哺乳動物之動物，例如家禽、豬、貓、狗、馬或兔。本發明組合物可用於增強動物之生長及性能。若投與動物，則可使用口服胃管灌食。在一些實施例中，投與組合物之個體係成人人類。在一些實施例中，投與組合物之個體係嬰兒人類。組合物通常，本發明組合物包含細菌。在本發明之較佳實施例中，將組合物調配成凍乾形式。舉例而言，本發明組合物可包含含有本發明細菌菌株之粒劑或明膠膠囊，例如硬質明膠膠囊。較佳地，本發明組合物包含凍乾細菌。細菌凍乾係充分確立程序且相關導則可獲得自(例如)參考文獻[25-27]。凍乾物組合物可尤其有效。在較佳實施例中，本發明組合物包含凍乾細菌且係用於治療與IBS有關之腹瀉及/或便秘。或者，本發明組合物可包含活的活性細菌培養物。實例證實，本發明細菌之培養物在治療上有效。在一些實施例中，本發明組合物中之細菌菌株尚未滅活，例如尚未熱滅活。在一些實施例中，本發明組合物中之細菌菌株尚未殺死，例如尚未熱殺死。在一些實施例中，本發明組合物中之細菌菌株尚未減弱，例如尚未熱減弱。舉例而言，在一些實施例中，尚未殺死、鈍化及/或減弱本發明組合物中之細菌菌株。舉例而言，在一些實施例中，本發明組合物中之細菌菌株係活的。舉例而言，在一些實施例中，本發明組合物中之細菌菌株可生長發育的。舉例而言，在一些實施例中，本發明組合物中之細菌菌株能夠部分地或完全定殖於腸中。舉例而言，在一些實施例中，本發明組合物中之細菌菌株可生長發育的且能夠部分地或完全定殖於腸中。在一些實施例中，組合物包含活細菌菌株及已殺死細菌菌株之混合物。在較佳實施例中，囊封本發明組合物以使得能夠將細菌菌株遞送至腸。囊封可保護組合物免於降解直至經由(例如)使用化學或物理刺激(例如壓力、酶促活性或物理崩解)進行破裂(此可藉由pH變化來觸發)而遞送於靶位置為止。可使用任何適當囊封方法。實例性囊封技術包括包裹於多孔基質內、附接或吸附於固體載劑表面上、藉由絮凝或使用交聯劑自我聚集及機械容納於微孔膜或微膠囊內。關於可用於製備本發明組合物之囊封之導則可獲得自(例如)參考文獻[28-29]。組合物可經口投與且可呈錠劑、膠囊或粉末之形式。囊封產物較佳，此乃因布勞特氏菌係厭氧菌。可包括其他成分(例如維他命C)作為氧清除劑及益菌素受質以改良活體內之遞送及/或部分或完全定殖及生長發育的。或者，本發明益生菌組合物可作為食物或囊封產品(例如基於乳液或乳清之發酵乳製產品)或作為醫藥產物經口投與。組合物可調配為益生菌。本發明組合物包括治療有效量之本發明細菌菌株。治療有效量之細菌菌株足以向患者施加有益效應。治療有效量之細菌菌株可足以使得遞送至及/或部分或完全定殖於患者腸中。舉例而言，用於成人人類之細菌之適宜日劑量可為約1 × 10³ 至約1 × 10¹¹ 群落形成單位(CFU)；例如約1 × 10⁷ 至約1 × 10¹⁰ CFU；在另一實例中約1 × 10⁶ 至約1 × 10¹⁰ CFU；在另一實例中約1 × 10⁷ 至約1 × 10¹¹ CFU；在另一實例中約1 × 10⁸ 至約1 × 10¹⁰ CFU；在另一實例中約1 × 10⁸ 至約1 × 10¹¹ CFU。在某些實施例中，細菌之劑量為至少10⁹ 個細胞/天，例如至少10¹⁰ 、至少10¹¹ 或至少10¹² 個細胞/天。在某些實施例中，相對於組合物之重量，組合物以約1 × 10⁶ 至約1 × 10¹¹ CFU/g (例如約1 × 10⁸ 至約1 × 10¹⁰ CFU/g)之量含有細菌菌株。劑量可為(例如) 1 g、3g、5g及10g。通常，視情況組合益生菌(例如本發明組合物)與至少一種適宜益菌素化合物。益菌素化合物通常係不可消化碳水化合物(例如寡醣或多醣或醣醇)，其並不降解或吸收於上消化道中。已知益菌素包括商業產品，例如菊糖及反式半乳-寡醣。在某些實施例中，相對於組合物之總重量，本發明益生菌組合物以約1重量%至約30重量% (例如5重量%至20重量%)之量包括益菌素化合物。碳水化合物可選自由以下組成之群：果糖-寡醣(或FOS)、短鏈果糖-寡醣、菊糖、異麥芽糖-寡醣、果膠、木糖-寡醣(或XOS)、幾丁聚醣-寡醣(或COS)、β-葡聚糖、阿拉伯膠改質及抗性澱粉、聚右旋糖、D-塔格糖、阿拉伯膠纖維、刺槐、燕麥及柑橘纖維。在一態樣中，益菌素係短鏈果糖-寡醣(簡明起見在下文中展示為FOS-c.c)；該等FOSs-c.c.並非可消化碳水化合物，其通常藉由甜菜醣之轉化所獲得且包括三個葡萄糖分子所鍵結之蔗糖分子。本發明組合物可包含醫藥上可接受之賦形劑或載劑。該等適宜賦形劑之實例可參見參考文獻[30]。用於治療應用之可接受載劑或稀釋劑為醫藥技術所熟知且闡述於(例如)參考文獻[31]中。適宜載劑之實例包括乳糖、澱粉、葡萄糖、甲基纖維素、硬脂酸鎂、甘露醇、山梨醇及諸如此類。適宜稀釋劑之實例包括乙醇、甘油及水。可根據預期投與途徑及標準醫藥實踐來選擇醫藥載劑、賦形劑或稀釋劑。醫藥組合物可包含任何適宜黏合劑、潤滑劑、懸浮劑、塗覆劑、增溶劑作為載劑、賦形劑或稀釋劑或除了載劑、賦形劑或稀釋劑以外包含該等適宜黏合劑、潤滑劑、懸浮劑、塗覆劑、增溶劑。適宜黏合劑之實例包括澱粉、明膠、天然醣類(例如葡萄糖、無水乳糖、自由流動乳糖、β-乳糖)、玉米甜味劑、天然及合成膠(例如阿拉伯膠、黃蓍膠或海藻酸鈉)、羧甲基纖維素及聚乙二醇。適宜潤滑劑之實例包括油酸鈉、硬脂酸鈉、硬脂酸鎂、苯甲酸鈉、乙酸鈉、氯化鈉及諸如此類。防腐劑、穩定劑、染料及甚至矯味劑可提供於醫藥組合物中。防腐劑之實例包括苯甲酸鈉、山梨酸、半胱胺酸及對羥基苯甲酸酯，舉例而言，在一些實施例中，防腐劑係選自苯甲酸鈉、山梨酸及對羥基苯甲酸酯。亦可使用抗氧化劑及懸浮劑。適宜載劑之另一實例係蔗糖。防腐劑之另一實例係半胱胺酸。本發明組合物可調配為食品。舉例而言，除本發明之治療效應外，食品可提供營養益處，例如以營養補充品形式。類似地，可調配食品以增強本發明組合物之味道或藉由類似於常用食物品項而非醫藥組合物來使組合物更有吸引力地消費。在某些實施例中，將本發明組合物調配為基於乳液之產品。術語「基於乳液之產品」意指具有不同脂肪含量之任一基於乳液或乳清之液體或半固體產品。基於乳液之產品可為(例如)牛乳、山羊乳、綿羊乳、脫脂乳液、全乳、自奶粉重組之乳液及未經任何處理之乳清或經處理產品(例如酸乳酪、凝固乳液、凝乳、酸奶、酸性全乳、酪乳及其他酸乳產品)。另一重要群包括乳液飲料，例如乳清飲料、發酵乳、煉乳、嬰兒或幼兒乳飲品；調味乳、冰淇淋；含乳食品，例如甜食。在一些實施例中，本發明組合物包含一或多種布勞特氏菌屬之細菌菌株且不含來自任一其他屬之細菌，或其僅包含微量或生物不相關量之來自另一屬之細菌。在某些實施例中，本發明組合物含有單一細菌菌株或物種且不含任何其他細菌菌株或物種。該等組合物可包含僅微量或生物不相關量之其他細菌菌株或物種。該等組合物可為實質上不含其他有機體物種之培養物。在一些實施例中，該等組合物可為實質上不含其他有機體物種之凍乾物。在某些實施例中，本發明組合物包含一或多種布勞特氏菌屬之細菌菌株(例如氫營養型布勞特氏菌)且不含任一其他細菌屬，或其包含僅微量或生物不相關量之來自另一屬之細菌。在某些實施例中，本發明組合物包含單一布勞特氏菌物種(例如氫營養型布勞特氏菌)且不含任一其他細菌物種，或其包含僅微量或生物不相關量之來自另一物種之細菌。在某些實施例中，本發明組合物包含單一布勞特氏菌菌株(例如氫營養型布勞特氏菌)且不含任一其他細菌菌株或物種，或其包含僅微量或生物不相關量之來自另一菌株或物種之細菌。在一些實施例中，本發明組合物包含一種以上細菌菌株或物種。舉例而言，在一些實施例中，本發明組合物包含一種以上來自同一物種內之菌株(例如大於1、2、3、4、5、6、7、8、9、10、15、20、25、30、35、40或45種菌株)且視情況不含來自任一其他物種之細菌。在一些實施例中，本發明組合物包含小於50種來自同一物種內之菌株(例如小於45、40、35、30、25、20、15、12、10、9、8、7、6、5、4或3種菌株)且視情況不含來自任一其他物種之細菌。在一些實施例中，本發明組合物包含1-40、1-30、1-20、1-19、1-18、1-15、1-10、1-9、1-8、1-7、1-6、1-5、1-4、1-3、1-2、2-50、2-40、2-30、2-20、2-15、2-10、2-5、6-30、6-15、16-25或31-50種來自同一物種內之菌株且視情況不含來自任一其他物種之細菌。在一些實施例中，本發明組合物包含一種以上來自同一屬內之物種(例如大於1、2、3、4、5、6、7、8、9、10、12、15、17、20、23、25、30、35或40種物種)，且視情況不含來自任一其他屬之細菌。在一些實施例中，本發明組合物包含小於50種來自同一屬內之物種(例如小於50、45、40、35、30、25、20、15、12、10、8、7、6、5、4或3種物種)，且視情況不含來自任一其他屬之細菌。在一些實施例中，本發明組合物包含1-50、1-40、1-30、1-20、1-15、1-10、1-9、1-8、1-7、1-6、1-5、1-4、1-3、1-2、2-50、2-40、2-30、2-20、2-15、2-10、2-5、6-30、6-15、16-25或31-50種來自同一屬內之物種且視情況不含來自任一其他屬之細菌。本發明包含前述情形之任一組合。在一些實施例中，組合物包含微生物聚生體。舉例而言，在一些實施例中，組合物包含作為微生物聚生體之一部分之布勞特氏菌細菌菌株。舉例而言，在一些實施例中，布勞特氏菌細菌菌株與一或多種(例如至少2、3、4、5、10、15或20種)來自其他屬之其他細菌菌株組合存在，該等菌株可在活體內共生性存活於腸中。舉例而言，在一些實施例中，組合物包含氫營養型布勞特氏菌之細菌菌株與來自不同屬之細菌菌株之組合。在一些實施例中，微生物聚生體包含兩種或更多種自單一有機體(例如人類)之糞便試樣獲得之細菌菌株。在一些實施例中，微生物聚生體並不一起發現於自然界中。舉例而言，在一些實施例中，微生物聚生體包含自至少兩種不同有機體之糞便試樣獲得之細菌菌株。在一些實施例中，兩種不同有機體係來自同一物種，例如兩個不同人類。在一些實施例中，兩種不同有機體係嬰兒人類及成人人類。在一些實施例中，兩種不同有機體係人類及非人類哺乳動物。在一些實施例中，本發明組合物另外包含與以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株具有相同安全性及治療效能特性之細菌菌株，但該細菌菌株並非以登錄號DSM 10507/14294寄存之氫營養型布勞特氏菌菌株或並非氫營養型布勞特氏菌或並非布勞特氏菌。在本發明組合物包含一種以上細菌菌株物、種或屬之一些實施例中，個別細菌菌株、物種或屬可分開、同時或依序投與。舉例而言，組合物可包含一種以上細菌菌株、物種或屬之全部，或細菌菌株、物種或屬可分開儲存且分開、同時或依序投與。在一些實施例中，分開儲存一種以上細菌菌株、物種或屬，但在使用之前混合在一起。在一些實施例中，用於本發明中之細菌菌株係自人類成人糞便獲得。在本發明組合物包含一種以上細菌菌株之一些實施例中，所有細菌菌株皆係獲得自人類成人糞便，或若存在其他細菌菌株，則其僅以微量存在。可在自人類成人糞便獲得且用於本發明組合物中之後培養細菌。在一些實施例中，一或多種布勞特氏菌細菌菌株係本發明組合物中之唯一治療活性劑。在一些實施例中，組合物中之細菌菌株係本發明組合物中之唯一治療活性劑。用於本發明中之組合物可或可不需要上市批准。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾該細菌菌株。在某些實施例中，本發明提供上述醫藥組合物，其中噴霧乾燥該細菌菌株。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾或噴霧乾燥細菌菌株且其中其係活的。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾或噴霧乾燥細菌菌株且其中其可生長發育的。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾或噴霧乾燥細菌菌株且其中其能夠部分地或完全定殖於腸中。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾或噴霧乾燥細菌菌株且其中其可生長發育的且能夠部分地或完全定殖於腸中。在一些情形下，在投與之前重構經凍乾或噴霧乾燥之細菌菌株。在一些情形下，藉由使用本文所闡述之稀釋劑來重構。本發明組合物可包含醫藥上可接受之賦形劑、稀釋劑或載劑。在某些實施例中，本發明提供一種醫藥組合物，其包含：本發明細菌菌株；及醫藥上可接受之賦形劑、載劑或稀釋劑；其中細菌菌株之量足以在投與有需要之個體時治療病症；及其中病症係腹瀉及/或便秘，例如與克羅恩氏病、潰瘍性結腸炎或更佳地IBS有關之腹瀉及/或便秘。在某些實施例中，本發明提供上述醫藥組合物，其中細菌菌株之量為約1 × 10³ 至約1 × 10¹¹ 群落形成單位/克組合物重量。在某些實施例中，本發明提供上述醫藥組合物，其中以1 g、3 g、5 g或10 g之劑量來投與組合物。在某些實施例中，本發明提供上述醫藥組合物，其中藉由選自由口服、直腸、皮下、鼻、經頰及舌下組成之群之方法來投與組合物。在某些實施例中，本發明提供上述醫藥組合物，其包含選自由乳糖、澱粉、葡萄糖、甲基纖維素、硬脂酸鎂、甘露醇及山梨醇組成之群之載劑。在某些實施例中，本發明提供上述醫藥組合物，其包含選自由乙醇、甘油及水組成之群之稀釋劑。在某些實施例中，本發明提供上述醫藥組合物，其包含選自由以下組成之群之賦形劑：澱粉、明膠、葡萄糖、無水乳糖、自由流動乳糖、β-乳糖、玉米甜味劑、阿拉伯膠、黃蓍膠、海藻酸鈉、羧甲基纖維素、聚乙二醇、油酸鈉、硬脂酸鈉、硬脂酸鎂、苯甲酸鈉、乙酸鈉及氯化鈉。在某些實施例中，本發明提供上述醫藥組合物，其進一步包含防腐劑、抗氧化劑及穩定劑中之至少一者。在某些實施例中，本發明提供上述醫藥組合物，其包含選自由苯甲酸鈉、山梨酸及對羥基苯甲酸酯組成之群之防腐劑。在某些實施例中，提供本發明醫藥組合物，其中該組合物不含任何礦物質，或更具體而言不含任一原子序數大於33之金屬，舉例而言，其中該組合物不含任何來自由硒、鉬、鎢、硒化合物、鉬化合物及鎢化合物組成之群之礦物質。在某些實施例中，本發明提供上述醫藥組合物，其中凍乾該細菌菌株。在某些實施例中，本發明提供上述醫藥組合物，其中在將組合物儲存於約4℃或約25℃下之密封容器中且將容器置於具有50%相對濕度之氣氛中時，至少80%之細菌菌株(如以群落形成單位所量測)在至少約1個月、3個月、6個月、1年、1.5年、2年、2.5年或3年之時段之後得以保留。在一些實施例中，將本發明組合物提供於包含如本文所闡述之組合物之密封容器中。在一些實施例中，密封容器係藥袋或瓶。在一些實施例中，將本發明組合物提供於包含如本文所闡述之組合物之注射器中。在一些實施例中，本發明組合物可提供為醫藥調配物。舉例而言，組合物可提供為錠劑或膠囊。在一些實施例中，膠囊係明膠膠囊(「gel-cap」)。在一些實施例中，經口投與本發明組合物。經口投與可涉及吞嚥(以使化合物進入胃腸道)及/或經頰、舌或舌下投與(藉此，該化合物直接自口腔進入血流)。適於經口投與之醫藥調配物包括固體栓塞、固體微粒、半固體及液體(包括多相或分散系統)，例如錠劑；含有多-或奈米顆粒之軟質或硬質膠囊、液體(例如水溶液)、乳液或粉劑；菱形錠劑(包括填充液體)；咀嚼劑；凝膠；快速分散劑型；膜；陰道錠；噴霧劑；及頰或黏膜黏著貼片。在一些實施例中，醫藥調配物係腸溶調配物，亦即適於藉由經口投與方式將本發明組合物遞送至腸之胃耐性調配物(例如抵抗胃pH)。當組合物之細菌或另一組分係酸敏感性時(例如，在胃條件下可輕易地降解)，腸溶調配物特別有用。在一些實施例中，腸溶調配物包含腸溶包衣。在一些實施例中，調配物係腸溶包衣劑型。舉例而言，調配物可為腸溶包衣錠劑或腸溶包衣膠囊或諸如此類。腸溶包衣可為習用腸溶包衣，例如用於經口遞送之錠劑、膠囊或諸如此類之習用包衣。調配物可包含膜包衣，例如腸溶聚合物(例如酸不溶性聚合物)之薄膜層。在一些實施例中，腸溶調配物本質性地是腸溶性的，例如胃耐性且無需腸溶包衣。因此，在一些實施例中，調配物係不包含腸溶包衣之腸溶調配物。在一些實施例中，調配物係自熱膠凝材料製得之膠囊。在一些實施例中，熱膠凝材料係纖維質材料，例如甲基纖維素、羥甲基纖維素或羥丙基甲基纖維素(HPMC)。在一些實施例中，膠囊包含不含任一成膜聚合物之殼體。在一些實施例中，膠囊包含殼體且殼體包含羥丙基甲基纖維素且不包含任一成膜聚合物(例如參見[32])。在一些實施例中，調配物本質性地係腸溶膠囊(例如來自Capsugel之Vcaps®)。在一些實施例中，調配物係軟質膠囊。軟質膠囊係可因添加潤滑劑(例如甘油、山梨醇、麥芽糖醇及聚乙二醇)存在於膠囊殼體中且具有某些彈性及柔軟性之膠囊。軟質膠囊可(例如)基於明膠或澱粉來產生。基於明膠之軟質膠囊可購自各個供應商。端視投與方法(例如經口或經直腸)，軟膠囊可具有各種形狀，其可(例如)為圓形、卵形、長方形或魚雷形。可藉由習用製程(例如藉由Scherer製程、Accogel製程或滴液或吹製製程)產生軟質膠囊。培養方法可使用標準微生物技術來培養用於本發明中之細菌菌株，如例如參考文獻[33-35]中所詳述。用於培養之固體或液體培養基可為(例如) YCFA瓊脂或YCFA培養基。YCFA培養基可包括(每100ml，近似值)：酪腖(1.0 g)、酵母提取物(0.25 g)、NaHCO₃ (0.4 g)、半胱胺酸(0.1 g)、K₂ HPO₄ (0.045 g)、KH₂ PO₄ (0.045 g)、NaCl (0.09 g)、(NH₄ )₂ SO₄ (0.09 g)、MgSO₄ · 7H₂ O (0.009 g)、CaCl₂ (0.009 g)、刃天青(0.1 mg)、氯化血紅素(1 mg)、生物素(1 μg)、鈷胺素(1 μg)、對胺基苯甲酸(3 μg)、葉酸(5 μg)及吡哆胺(15 μg)。概述除非另外指示，否則本發明實踐將採用熟習此項技術者已知之習用化學、生物化學、分子生物學、免疫學及藥理學方法。該等技術於文獻中充分解釋。例如參見參考文獻[36-43]等。術語「包含」涵蓋「包括」以及「由…組成」，舉例而言，「包含」X之組合物可唯一地由X組成或可包括其他物項，例如X + Y。與數值x 相關之術語「約」係可選的且意指(例如)x ±10%。詞語「實質上」不排除「完全」，舉例而言，「實質上不含」Y之組合物可完全不含Y。若需要，詞語「實質上」可自本發明之定義省略。所提及兩個核苷酸序列之間之序列一致性百分比意指，在比對時，該百分比之核苷酸在比對兩個序列時相同。此比對及同源性或序列一致性百分比可使用業內已知軟體程式(例如闡述於參考文獻[44]之第7.7.18部分中者)來測定。較佳比對係藉由Smith-Waterman同源性搜尋算法使用仿射性空位搜尋來測定，空位開放罰分為12且空位擴展罰分為2，BLOSUM矩陣為62。Smith-Waterman同源性搜尋算法揭示於參考文獻[45]中。除非具體陳述，否則包含諸多步驟之製程或方法可在方法開頭或末尾包含其他步驟，或可包含其他插入步驟。同樣，若適當，則該等步驟可以替代順序組合、省略或實施。本文闡述本發明之各個實施例。應瞭解，在每一實施例中所指定之特徵可與其他指定特徵組合以提供其他實施例。特定而言，本文突出顯示為適宜、典型或較佳之實施例可彼此組合(在其互相排斥時除外)。實施本發明之模式實例1 –I期臨床試驗期間之患者症狀變化實施I期臨床試驗，其中將氫營養型布勞特氏菌(「布勞替克」，以登錄號DSM 10507亦及以登錄號DSM 14294寄存之菌株)投與刺激性腸症候群(IBS)人類患者。在投藥期(第1-16天)期間向患者投與布勞替克且清除期為第19-23天。發現布勞替克較為安全且充分耐受。監測到4種症狀，其中之兩者係腹瀉及便秘。該研究記錄患者經歷該等症狀中之每一者發生改良、無變化抑或惡化。將來自投與布勞替克之患者之結果與彼等使用投與安慰劑之患者獲得之結果進行比較。在以下三個時間點監測症狀：第1天、第15/16天及在研究結束時。結果展示於圖1及2中。在比較患者之第16天報告症狀與來自第1天之基線時，接收布勞替克之17名IBS患者中之82%報告改良症狀(圖1)。症狀(其中之兩者係腹瀉及便秘)改良支持使用布勞替克來治療或預防腹瀉及/或便秘。 50%之接收安慰劑之患者報告改良症狀(圖1)。高安慰劑反應率係IBS臨床研究中之確立現象。基於相對於安慰劑之極小改良，西法先(Xifaxan)最新批准用於治療IBS (參見：http://www.accessdata.fda.gov/spl/data/5ab6fceb-4d22-4480-81fc-8bc28c16770d/5ab6fceb-4d22-4480-81fc-8bc28c16770d.xml )。基於本文所呈現之教示內容，預計與在投藥完成時(第16天)存在之症狀相比，在研究完成時症狀有所惡化(第19-23天)。此症狀惡化可見於I期臨床試驗中：41%之IBS患者在中止布勞替克投藥後報告症狀惡化(圖2)。在中止布勞替克投藥後之症狀(其中之兩者係腹瀉及便秘)惡化由此亦支持使用布勞替克來治療或預防腹瀉及/或便秘。實例2 –氫呼吸測試結果呼吸氫濃度係布勞替克活性之生物標記– MoA涉及內源性H₂ 產生乙酸鹽之代謝。向人類個體投與乳酮糖且在以下4個時間點採樣氫(H₂ )濃度(Cmax)：第1天、第2天、第15天及第16天。將氫未校正結果轉化成氫校正結果。自分析排除一些患者。存在以下三個導致個體不能包括於氫呼吸測試分析中之原因：1)其在4個採樣日期之一產生＜20之CMAX氫呼吸測試結果且由此視為對測試不具有反應；2)其係甲烷產生者(認為在呼吸測試中產生多於氫之甲烷)，此影響氫反應；及/或3)在氫呼吸測試中獲得異常值(232 ppm)。將個體3.12 (布勞替克)、3.24 (布勞替克)、4.07 (布勞替克)作為無反應者排除。將個體3.03 (布勞替克)及3.08 (安慰劑)作為甲烷產生者排除(所提及如上文所排除之4.07亦係甲烷產生者)。個體4.09 (安慰劑)因異常值而排除。將來自投藥期(第15/16天)結束之校正氫分析之結果與彼等來自基線(第1/2天)之結果進行比較。接收布勞替克之12名患者中之10名(83%)在此時段之氫濃度有所降低(圖3a及3c)。與之相比，接收安慰劑之6名患者中之3名 (50%)具有降低之氫濃度(圖3b及3c)。該等百分比類似於在布勞替克治療或投與安慰劑後展現改良症狀之患者之百分比。圖4展示布勞替克(Verum)治療組之未校正及校正氫結果以及該等結果之統計學分析。發現未校正及校正H₂ 之平均值在第1天與第15天之間有所不同。在治療13.5天之後，在乳酮糖刺激之後檢測到Cmax呼吸測試中之H₂ 在統計學上顯著(p ＜ 0.05)降低。與之相比，對於安慰劑組而言，發現在第1天及第15天之平均值等效(p ＞ 0.05) (圖5)。因此，對於未校正氫結果及校正氫結果而言，治療組(亦稱為VERUM組)之平均值在第1天與第15天之間有所降低，而安慰劑組之平均值在第1天與第15天之間等效(圖6)。實例 3 – 穩定性測試 將本文所闡述含有至少一種本文所闡述細菌菌株之組合物儲存於25℃或4℃下之密封容器中且將容器置於具有30%、40%、50%、60%、70%、75%、80%、90%或95%相對濕度之氣氛中。在1個月、2個月、3個月、6個月、1年、1.5年、2年、2.5年或3年之後，至少50%、60%、70%、80%或90%之細菌菌株應得以保留，如以藉由標準方案測定之群落形成單位所量測。序列 SEQ ID NO:1 (糞堆布勞特氏菌菌株GAM6-1 16S核糖體RNA基因，部分序列- HM626177) 1 tgcaagtcga gcgaagcgct tacgacagaa ccttcggggg aagatgtaag ggactgagcg 61 gcggacgggt gagtaacgcg tgggtaacct gcctcataca gggggataac agttggaaac 121 ggctgctaat accgcataag cgcacggtat cgcatgatac agtgtgaaaa actccggtgg 181 tatgagatgg acccgcgtct gattagctag ttggaggggt aacggcccac caaggcgacg 241 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc 301 ctacgggagg cagcagtggg gaatattgca caatggggga aaccctgatg cagcgacgcc 361 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaaga aaatgacggt 421 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca 481 agcgttatcc ggatttactg ggtgtaaagg gagcgtagac ggaagagcaa gtctgatgtg 541 aaaggctggg gcttaacccc aggactgcat tggaaactgt ttttcttgag tgccggagag 601 gtaagcggaa ttcctagtgt agcggtgaaa tgcgtagata ttaggaggaa caccagtggc 661 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg 721 attagatacc ctggtagtcc acgccgtaaa cgatgaatac taggtgttgg ggagcaaagc 781 tcttcggtgc cgcagcaaac gcaataagta ttccacctgg ggagtacgtt cgcaagaatg 841 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag 901 caacgcgaag aaccttacca agtcttgaca tcgatctgac cggttcgtaa tggaaccttt 961 ccttcgggac agagaagaca ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt 1021 gggttaagtc ccgcaacgag cgcaacccct atcctcagta gccagcaggt gaagctgggc 1081 actctgtgga gactgccagg gataacctgg aggaaggcgg ggacgacgtc aaatcatcat 1141 gccccttatg atttgggcta cacacgtgct acaatggcgt aaacaaaggg aagcgagccc 1201 gcgaggggga gcaaatccca aaaataacgt cccagttcgg actgcagtct gcaactcgac 1261 tgcacgaagc tggaatcgct agtaatcgcg aatcagaatg tcgcggtgaa tacgttcccg 1321 ggtcttgtac acaccgcccg tcacaccatg ggagtcagta acgcccgaag tc SEQ ID NO:2 (魏克拉-布勞特氏菌菌株WAL 14507 16S核糖體RNA基因，部分序列- EF036467) 1 caagtcgaac gggaattant ttattgaaac ttcggtcgat ttaatttaat tctagtggcg 61 gacgggtgag taacgcgtgg gtaacctgcc ttatacaggg ggataacagt cagaaatggc 121 tgctaatacc gcataagcgc acagagctgc atggctcagt gtgaaaaact ccggtggtat 181 aagatggacc cgcgttggat tagcttgttg gtggggtaac ggcccaccaa ggcgacgatc 241 catagccggc ctgagagggt gaacggccac attgggactg agacacggcc cagactccta 301 cgggaggcag cagtggggaa tattgcacaa tgggggaaac cctgatgcag cgacgccgcg 361 tgaaggaaga agtatctcgg tatgtaaact tctatcagca gggaagatag tgacggtacc 421 tgactaagaa gccccggcta actacgtgcc agcagccgcg gtaatacgta gggggcaagc 481 gttatccgga tttactgggt gtaaagggag cgtagacggt gtggcaagtc tgatgtgaaa 541 ggcatgggct caacctgtgg actgcattgg aaactgtcat acttgagtgc cggaggggta 601 agcggaattc ctagtgtagc ggtgaaatgc gtagatatta ggaggaacac cagtggcgaa 661 ggcggcttac tggacggtaa ctgacgttga ggctcgaaag cgtggggagc aaacaggatt 721 agataccctg gtagtccacg ccgtaaacga tgaataacta ggtgtcgggt ggcaaagcca 781 ttcggtgccg tcgcaaacgc agtaagtatt ccacctgggg agtacgttcg caagaatgaa 841 actcaaagga attgacgggg acccgcacaa gcggtggagc atgtggttta attcgaagca 901 acgcgaagaa ccttaccaag tcttgacatc cgcctgaccg atccttaacc ggatctttcc 961 ttcgggacag gcgagacagg tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg 1021 gttaagtccc gcaacgagcg caacccctat cctcagtagc cagcatttaa ggtgggcact 1081 ctggggagac tgccagggat aacctggagg aaggcgggga tgacgtcaaa tcatcatgcc 1141 ccttatgatt tgggctacac acgtgctaca atggcgtaaa caaagggaag cgagattgtg 1201 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac 1261 acgaagctgg aatcgctagt aatcgcggat cagaatgccg cggtgaatac gttcccgggt 1321 cttgtacaca ccgcccgtca caccatggga gtcagtaacg cccgaagtca gtgacctaac 1381 tgcaaagaag gagctgccga aggcgggacc gatgactggg gtgaagtcgt aacaaggt SEQ ID NO:3 (糞堆布勞特氏菌菌株830之共有16S rRNA序列) TTTKGTCTGGCTCAGGATGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAGCGAAGCGCTTACGACAGAACCTTCGGGGGAAGATGTAAGGGACTGAGCGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTCATACAGGGGGATAACAGTTGGAAACGGCTGCTAATACCGCATAAGCGCACAGTATCGCATGATACAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGGGCTTAACCCCAGGACTGCATTGGAAACTGTTTTTCTTGAGTGCCGGAGAGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTTGGGGAGCAAAGCTCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCGATCTGACCGGTTCGTAATGGAACCTTTCCTTCGGGACAGAGAAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCGTCAGTAGCCAGCAGGTAAAGCTGGGCACTCTGAGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGACGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCCGCGAGGGGGAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGAAGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCCAACCTTAGGGAGGGAGCTGCCGAAGGCGGGATTGATAACTGGGGTGAAGTCTAGGGGGT SEQ ID NO:4 (魏克拉-布勞特氏菌菌株MRX008之共有16S rRNA序列) TTCATTGAGACTTCGGTGGATTTAGATTCTATTTCTAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTTATACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGCATAAGCGCACAGAGCTGCATGGCTCAGTGTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTTGGATTAGCTTGTTGGTGGGGTAACGGCCCACCAAGGCGACGATCCATAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGATAGTGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTGTGGCAAGTCTGATGTGAAAGGCATGGGCTCAACCTGTGGACTGCATTGGAAACTGTCATACTTGAGTGCCGGAGGGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCNGGGGAGCATGGCTCTTCGGTGCCGTCGCAAACGCAGTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCCGCCTGACCGATCCTTAACCGGATCTTTCCTTCGGGACAGGCGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCCTCAGTAGCCAGCATTTAAGGTGGGCACTCTGGGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGATCGTGAGATGGAGCAAATCCCAAAAATAACGTCCCAGTTCGGACTGTAGTCTGCAACCCGACTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA SEQ ID NO:5 (氫營養型布勞特氏菌S5a36 16S核糖體RNA基因，部分序列- X95624.1) 1 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatag agaacggaga 61 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tgggtaacct 121 gccctataca gggggataac agttagaaat gactgctaat accgcataag cgcacagctt 181 cgcatgaagc ggtgtgaaaa actgaggtgg tataggatgg acccgcgttg gattagctag 241 ttggtgaggt aacggcccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc 301 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 361 caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct cggtatgtaa 421 acttctatca gcagggaaga aagtgacggt acctgactaa gaagccccgg ctaattacgt 481 gccagcagcc gcggtaatac gtaaggggca agcgttatcc ggatttactg ggtgtaaagg 541 gagcgtagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 601 tggaaactgt cagacttgag tgccggagag gcaagcggaa ttcctagtgt agcggtgaaa 661 tgcgtagata ttaggaggaa caccagtggc gaaggcggcc tgctggacgg taactgacgt 721 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 781 cgatgaatac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaaac gcaataagta 841 ttcccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 901 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac 961 atccctctga ccgggaagta atgttccctt ttcttcggaa cagaggagac aggtggtgca 1021 tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1081 tattcttagt agccagcagg tagagctggg cactctaggg agactgccag ggataacctg 1141 gaggaaggtg gggatgacgt caaatcatca tgccccttat gatttgggct acacacgtgc 1201 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1261 tctcagttcg gattgtagtc tgcaactcga ctacatgaag ctggaatcgc tagtaatcgc 1321 gaatcagaat gtcgcggtga atacgttccc gggtcttgta cacaccgccc gtcacaccat 1381 gggagtcagt aacgcccgaa gtcagtgacc caaccnaaag gagggagctg ccgaaggtgg 1441 gactgataac tggggtga參考文獻 [1] Spor等人(2011)Nat Rev Microbiol . 9(4):279-90. [2] Eckburg等人(2005)Science . 10;308(5728):1635-8. [3] Tap等人(2009)Environ Microbiol, 11(10):2574-84 [4] Macpherson等人(2001)Microbes Infect . 3(12):1021-35 [5] Macpherson等人(2002)Cell Mol Life Sci. 59(12):2088-96. [6] Mazmanian等人(2005)Cell 15;122(1):107-18. [7] Frank等人(2007)PNAS 104(34):13780-5. [8] Scanlan等人(2006)J Clin Microbiol . 44(11):3980-8. [9] Kang等人(2010)Inflamm Bowel Dis . 16(12):2034-42. [10] Machiels等人(2013)Gut . 63(8):1275-83. [11] Lopetuso等人(2013), Gut Pathogens, 5: 23 [12] WO 2013/050792 [13] WO 03/046580 [14] WO 2013/008039 [15] WO 2014/167338 [16] Lee及Lee (2014)World J Gastroenterol. 20(27): 8886-8897. [17] Liu等人(2008)Int J Syst Evol Microbiol 58, 1896–1902. [18] Bernalier等人(1996)Arch. Microbiol. 166 (3), 176-183. [19] Park等人(2012)Int J Syst Evol Microbiol. 62(Pt 4):776-9. [20] Masco等人(2003)Systematic and Applied Microbiology, 26:557-563. [21] Srůtková等人(2011)J. Microbiol. Methods , 87(1):10-6. [22] Darfeuille-Michaud等人(2004)Gastroenterology 127(2):412-21. [23] Strus等人(2015)Cent Eur J Immunol .40(4):420-30. [24] Petersen等人(2015)Scand J Gastroenterol .;50(10):1199-207. [25] Miyamoto-Shinohara等人(2008)J. Gen. Appl. Microbiol. , 54, 9–24. [26] Cryopreservation and Freeze-Drying Protocols，由Day and McLellan編輯，Humana Press. [27] Leslie等人(1995)Appl. Environ. Microbiol. 61, 3592–3597. [28] Mitropoulou等人(2013)J Nutr Metab . (2013) 716861. [29] Kailasapathy等人(2002)Curr Issues Intest Microbiol. 3(2):39-48. [30] Handbook of Pharmaceutical Excipients，第2版(1994)，由A Wade and PJ Weller編輯 [31] Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro編輯，1985) [32] US 2016/0067188 [33]Handbook of Microbiological Media, Fourth Edition ( 2010) Ronald Atlas, CRC Press. [34]Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academic Press [35] Strobel (2009)Methods Mol Biol . 581:247-61. [36] Gennaro (2000)Remington: The Science and Practice of Pharmacy. 第20版，ISBN: 0683306472. [37]Molecular Biology Techniques: An Intensive Laboratory Course , (Ream等人編輯，1998, Academic Press). [38]Methods In Enzymology (S. Colowick and N. Kaplan編輯，Academic Press, Inc.) [39]Handbook of Experimental Immunology ，第I-IV卷(D.M. Weir及C.C. Blackwell編輯，1986, Blackwell Scientific Publications) [40] Sambrook等人(2001)Molecular Cloning: A Laboratory Manual ，第3版(Cold Spring Harbor Laboratory Press). [41]Handbook of Surface and Colloidal Chemistry (Birdi, K.S.編輯，CRC Press, 1997) [42] Ausubel等人(編輯) (2002)Short protocols in molecular biology ，第5版(Current Protocols). [43]PCR (Introduction to Biotechniques Series )，第2版(Newton & Graham編輯，1997, Springer Verlag) [44]Current Protocols in Molecular Biology (F.M. Ausubel等人編輯，1987)增刊30 [45] Smith & Waterman (1981)Adv. Appl. Math. 2: 482-489.Bacterial Strains The compositions of the invention comprise bacterial strains of the genus Blautia. Examples have demonstrated that this genus of bacteria can be used to treat or prevent diarrhea and/or constipation. Preferred bacterial strains are the species hydrogenotrophic Brautia , Brautia faecalis and Brautia weiklar-Broutia . Other preferred bacterial strains for use in the present invention are Blautia producta , Blautia coccoides and Blautia hansenii . Examples of Blautia strains useful in the present invention include Hydrogenotrophic Blautia, Blautia faecalis , B. faecis , Blautia globosa , B. glucerasea, Hansen-Broutia, Luti-Brouteria ( B. luti ), Broutia elongatum, Shienji-Broutia Lauteria ( B. schinkii ) and Weikla-Broutieria. Blautia spp. are Gram-reaction-positive, non-motile bacteria that can be spherical or oval in shape and are all absolutely anaerobic bacteria that produce acetic acid as the main end product of glucose fermentation [17 ]. Broutia can be isolated from human intestines, but Broutia elongatus is isolated from septic samples. The hydrogenotrophic Blautia bacterium (formerly known as Ruminococcus hydrogenotrophicus ) has been isolated from mammalian intestines, is strictly anaerobic, and metabolizes _H2 / _CO2 into More important acetate. The strain type of hydrogenotrophic Blautia is S5a33 = DSM 10507 = JCM 14656. The GenBank accession number of the 16S rRNA gene sequence of the hydrogenotrophic Blautia strain S5a36 is X95624.1 (revealed herein as SEQ ID NO: 5). Such exemplary hydrogenotrophic Blautia strains are described in [17] and [18]. The S5a33 strain and the S5a36 strain correspond to two subpure lines of the strains isolated from the stool samples of healthy individuals. They display the same morphology, physiology and metabolism and the same 16S rRNA sequence. Therefore, in some embodiments, the hydrogenotrophic Blautia spp. used in the present invention has the 16S rRNA sequence of SEQ ID NO:5. The hydrogenotrophic Blautia bacterium deposited under accession number DSM 10507 and also under accession number DSM 14294 was tested in the Examples and is also referred to herein as strain BH. Deutsche Sammlung von Mikroorganismen [German Microorganism Collection] (Mascheroder Weg 1b, 38124 Braunschweig, Germany) deposited strain BH under accession number DSM 10507 in January 1996 as "Rumenococcus hydrogenotroph" and also Deposited as "S5a33" on May 10, 2001 under accession number DSM 14294. The depositor is INRA Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122 Saint Genès Champanelle, France. Title to the deposit has passed to 4D Pharma Plc by assignment. The GenBank accession number of the 16S rRNA gene sequence of B. faecalis strain GAM6-1 ^T is HM626177 (revealed herein as SEQ ID NO: 1). Exemplary B. faecalis strains are described in [19]. The strain type of Wickla-Broutia is WAL 14507 = ATCC BAA-1564 = DSM 19850 [17]. The GenBank accession number of the 16S rRNA gene sequence of the Weiklar-Broutia strain WAL 14507 T is EF036467 (revealed herein as SEQ ID NO: 2). This exemplary Brautia weiklari strain is described in [17]. A preferred B. faecalis strain is the strain deposited under accession number NCIMB 42381, which is also referred to herein as strain 830. The 16S rRNA sequence of the 830 strain is provided in SEQ ID NO:3. Strain 830 was deposited by GT Biologics Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Scotland) as " Broutia faecalis 830" and assigned accession number NCIMB 42381. GT Biologics Ltd. subsequently changed its name to 4D Pharma Research Limited. A preferred strain of Brautia weiklarii is the strain deposited under accession number NCIMB 42486, which is also referred to herein as strain MRX008. The 16S rRNA sequence of the MRX008 strain is provided in SEQ ID NO:4. Strain MRX008 was deposited by 4D Pharma Research Ltd. (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Scotland) on November 16, 2015 as "Broutia / Ruminococcus MRx0008 " and assigned accession number NCIMB 42486. Bacterial strains closely related to the strains tested in the Examples are also expected to be effective in treating or preventing diarrhea and/or constipation. In certain embodiments, the bacterial strains used in the present invention have at least 95%, 96%, 97%, 98%, 99%, 99.5% of the 16s rRNA sequence of the bacterial strains of hydrogenotrophic Blautia Or 99.9% identical 16s rRNA sequence. Preferably, the bacterial strain used in the present invention has a 16s rRNA sequence at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:5. In certain embodiments, the bacterial strain used in the present invention has a 16s rRNA sequence at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% identical 16s rRNA sequence. Preferably, the bacterial strain used in the present invention has 16s rRNA that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO: 1 or SEQ ID NO: 3 sequence. Preferably, the sequence identity is to SEQ ID NO:3. Preferably, the bacterial strain used in the present invention has a 16s rRNA sequence represented by SEQ ID NO:3. In certain embodiments, the bacterial strains used in the present invention have at least 95%, 96%, 97%, 98%, 99%, 99.5% of the 16s rRNA sequence of the bacterial strains of Brautia weiklarii Or 99.9% identical 16s rRNA sequence. Preferably, the bacterial strain used in the present invention has 16s rRNA that is at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical to SEQ ID NO:2 or SEQ ID NO:4 sequence. Preferably, the sequence identity is to SEQ ID NO:4. Preferably, the bacterial strain used in the present invention has a 16s rRNA sequence represented by SEQ ID NO:4. Bacterial strains that are bacterial biotypes deposited under accession numbers DSM 10507/14294 or bacterial biotype lines deposited under accession numbers NCIMB 42381 and NCIMB 42486 are also expected to be effective in the treatment or prevention of diarrhea and/or constipation. Biotypes are closely related strains with identical or very similar physiological and biochemical properties. Bacterial strains suitable for use in the present invention as bacterial biotypes deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 can be obtained by sequencing other nuclei of bacteria deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486. nucleotide sequence for identification. For example, a biotype strain that can sequence substantially its entire genome and for use in the present invention can have at least 80% of its entire genome (e.g., at least 85%, 90%, 95%, or 99%, or Across its entire genome) have at least 95%, 96%, 97%, 98%, 99%, 99.5%, or 99.9% sequence identity. For example, in some embodiments, a biotype strain has at least 98% sequence identity in at least 98% of its genomes or at least 99% sequence identity in 99% of its genomes. Other suitable sequences for use in the identified biotype strains may include hsp60 or repeat sequences (eg BOX, ERIC, (GTG) ₅ or REP or [20]). The biotype strain may have at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% sequence identity to the corresponding sequence of the bacterium deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 sequence. In some embodiments, the biotype strain has at least 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to the corresponding sequence of the hydrogenotrophic Blautia strain deposited as DSM 10507/14294. sequence and comprising a 16S rRNA sequence that is at least 99% identical (eg, at least 99.5% or at least 99.9% identical) to SEQ ID NO:5. In some embodiments, the biotype strain has at least 97%, 98%, 99%, 99.5%, or 99.9% sequence identity to the corresponding sequence of the hydrogenotrophic Blautia strain deposited as DSM 10507/14294. sequence and has the 16S rRNA sequence of SEQ ID NO:5. Alternatively, bacterial strains suitable for use in the present invention as bacterial biotypes deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 can be obtained by using deposit accession numbers DSM 10507/14294, deposit accession numbers NCIMB 42381 or deposit accession numbers NCIMB 42486 and restriction fragment analysis and/or PCR analysis (e.g. by using fluorescent amplified fragment length polymorphism (FAFLP) and repetitive DNA element (rep)-PCR fingerprinting or protein profiling or partial 16S or 23S rDNA sequencing) to identify. In preferred embodiments, these techniques can be used to identify other hydrogenotrophic, B. faecalis, or B. weiklar-Broutia strains. In certain embodiments, strains suitable for use in the present invention as bacterial biotypes deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 are analyzed by amplified ribosomal DNA restriction analysis (ARDRA) (eg when using the Sau3AI restriction enzyme) (see eg [21] for exemplary methods and guidelines) Bacteria deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 provide strains of the same pattern. Alternatively, biotype strains were identified as strains having the same carbohydrate fermentation pattern as bacteria deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486. Any suitable method or strategy, including the assays set forth in the examples, can be used to identify other strains of Blautia that can be used in the compositions and methods of the invention (e.g., under accession numbers DSM 10507/14294, NCIMB 42381 or Biotypes of bacteria deposited in NCIMB 42486). For example, strains for use in the present invention can be identified by culturing the bacteria and administering to rats for testing in an expansion assay. In particular, bacterial strains having a similar growth pattern, metabolic type and/or surface antigens to bacteria deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 may be used in the present invention. Useful strains will have comparable microflora modulating activity to DSM 10507/14294, NCIMB 42381 or NCIMB 42486 strains. In particular, biotype strains induce effects on diarrhea and/or constipation comparable to those shown in the Examples, which effects can be identified using the incubation and administration protocols described in the Examples. A preferred strain of the present invention is the hydrogenotrophic Blautia strain deposited under accession number DSM 10507/14294. This is an exemplary BH strain tested in the Examples and shown to be effective in treating disease. Accordingly, the present invention provides cells (eg isolated cells) of the hydrogenotrophic Blautia strain deposited under accession number DSM 10507/14294 or a derivative thereof for use in therapy, especially for use in the diseases described herein. Derivatives of strains deposited under accession numbers DSM 10507/14294, NCIMB 42381 or NCIMB 42486 may be daughter strains (progeny) or strain cultures from the original strain (subselection). Derivatives of the strains of the invention can be modified (for example at the genetic level) without removing biological activity. In particular, the derivative strains of the invention have therapeutic activity. The derived strains had comparable microflora modulating activity to the original DSM 10507/14294, NCIMB 42381 or NCIMB 42486 strains. In particular, the derivative strains induce effects on diarrhea and/or constipation comparable to those shown in the Examples, which effects can be identified using the incubation and administration protocols described in the Examples. Derivatives of the DSM 10507/14294 strain are generally biotypes of the DSM 10507/14294 strain. Derivatives of the NCIMB 42381 strain are generally biotypes of the NCIMB 42381 strain. Derivatives of the NCIMB 42486 strain are generally biotypes of the NCIMB 42486 strain. Reference to cells of the hydrogenotrophic Blautia strain deposited under accession number DSM 10507/14294 covers any cell having the same safety and therapeutic efficacy properties as the strain deposited under accession number DSM 10507/14294, and which Cells are encompassed by the invention. Reference to cells of the strain of B. faecalis deposited under accession number NCIMB 42381 encompasses any cell having the same safety and therapeutic efficacy properties as the strain deposited under accession number NCIMB 42381 and such cells are encompassed by the present invention. Reference to cells of the strain of Brautia weiclae deposited under accession number NCIMB 42486 encompasses any cell having the same safety and therapeutic efficacy properties as the strain deposited under accession number NCIMB 42486, and such cells are covered by the present invention . In preferred embodiments, the bacterial strains in the composition of the present invention are vegetative and capable of partially or completely colonizing the intestine. Therapeutic Uses In preferred embodiments, the compositions of the present invention are used to treat diarrhea and/or constipation. In some embodiments, the compositions are used to treat patients suffering from diarrhea and constipation. In some embodiments, the composition is used to treat a patient with diarrhea but not constipation. In some embodiments, the composition is used to treat a patient with constipation but not diarrhea. Although patients typically present with either diarrhea or constipation, individual patients may present with both conditions at different times. Patients with IBS and/or bowel inflammatory diseases often exhibit diarrhea and/or constipation. Accordingly, the present invention provides compositions of the invention for use in the treatment of a patient diagnosed with or suspected of having IBS or an inflammatory bowel disease. For example, an IBS patient may experience alternating cycles of diarrhea and constipation or an IBS patient may be described as an IBS patient with diarrhea or an IBS patient with constipation. In some embodiments, a composition of the invention may be used to treat an IBS patient, an IBS patient with diarrhea, or an IBS patient with constipation. For example, in some embodiments, an individual diagnosed with IBS has IBS with both diarrhea and constipation. In some embodiments, the individual diagnosed with IBS has IBS with diarrhea and no constipation or with only mild constipation. In some embodiments, the individual diagnosed with IBS has IBS with constipation but no diarrhea or with only a small amount of diarrhea. In some embodiments, the inflammatory disease is a disease of the small intestine, colon or rectum. Diarrhea is a symptom of Crohn's disease and ulcerative colitis. Thus, patients with Crohn's disease or ulcerative colitis may be treated using the compositions of the invention. As demonstrated in the Examples, the bacterial composition of the present invention is effective for alleviating diarrhea and/or constipation. In a preferred embodiment, the composition of the present invention is used in the treatment or prevention of diarrhea and/or constipation associated with Crohn's disease, ulcerative colitis or more preferably IBS. In preferred embodiments, the compositions of the present invention are used to treat or prevent diarrhea and/or constipation in individuals diagnosed with Crohn's disease, ulcerative colitis or more preferably IBS. In a preferred embodiment, the composition of the present invention is used for the treatment or prevention of diarrhea and/or constipation in the treatment of Crohn's disease, ulcerative colitis or more preferably IBS. In some embodiments, the patient suffers from abdominal pain and/or bloating in addition to diarrhea and/or constipation. In these embodiments, the patient may suffer from any combination of two, three, or all four of these conditions. For example, a patient may suffer from diarrhea, constipation, abdominal pain and flatulence; diarrhea, constipation and abdominal pain; diarrhea, constipation and flatulence; diarrhea, abdominal pain and/or flatulence without constipation; constipation, abdominal pain and/or Or flatulence, no diarrhea. In certain embodiments, the composition may be in the form of a bacterial culture. In some embodiments, the composition may preferably be a lyophilizate. In some embodiments, compositions of the invention are used to treat diarrhea and/or constipation in subjects with increased hydrogen concentrations in the breath relative to healthy subjects. In some embodiments, compositions of the invention are used to reduce the concentration of hydrogen in the breath of a subject suffering from diarrhea and/or constipation. The individual is preferably an individual diagnosed with IBS and/or an inflammatory bowel disease. In some embodiments, the inflammatory disease is a disease of the small intestine, colon or rectum. In some embodiments, the individual has been diagnosed with Crohn's disease, ulcerative colitis, or more preferably IBS, such as the type of IBS described herein. Without being bound by theory, it is hypothesized that the increased hydrogen concentration arises from an underlying mechanism of intestinal inflammation. The examples demonstrate that treatment with the compositions of the invention reduces the hydrogen concentration detected in the hydrogen breath test. Therefore, it is preferable to use a hydrogen breath test to evaluate the hydrogen concentration. The hydrogen breath test is well known in the art and thus those skilled in the art know how to perform such a test. In some embodiments, lactulose is administered to a patient as a test substrate. The hydrogen breath test is also a useful tool for monitoring the effectiveness, or likely effectiveness, of using the compositions of the invention for treatment or prophylaxis. For example, a decrease in the concentration of hydrogen detected in the breath of an individual following treatment or prophylaxis by a composition of the invention may indicate that the treatment has a therapeutic or prophylactic effect. Thus, in some embodiments, the methods and uses of the present invention further comprise monitoring the hydrogen concentration in the breath of the individual during and/or after treatment or prophylaxis with the composition of the present invention and thereby assessing the effectiveness or likelihood of efficacy of the treatment or prophylaxis sex. For example, the hydrogen concentration may be monitored one or more times (e.g., 1, 2, 3, 4, or more than 4 times), e.g., including before treatment, at the beginning of treatment, during treatment, at the end of treatment, and/or at After treatment. In some embodiments, the concentration of hydrogen in the breath of the subject at and/or after the end of the dosing period (during which the composition is administered to the subject) is compared to the concentration at the beginning of and/or before the dosing period, and a decrease in the concentration is indicative of treatment or the effectiveness or likely effectiveness of prevention. For example, in an embodiment where the dosing period is 16 days, it may be desirable to take measurements on days 1 and 16 or, for example, on days 1, 2, 15 and 16. In some embodiments, multiple measurements are taken and an average of those measurements is obtained (eg, the average of days 1 and 2 and the average of days 15 and 16). In some embodiments, a decrease in the hydrogen concentration Cmax of at least 40 ppm is indicative that the treatment or prophylaxis is or is likely to be effective. In some embodiments, the concentration of hydrogen in an individual's breath is measured only once (eg, at or after the end of treatment), and when the concentration is found to be at or near a predetermined concentration, it may indicate that treatment or prevention may be effective. The hydrogen breath test is a standard assay and thus the predetermined concentration is known in the industry. In certain embodiments, the compositions of the invention are used for the prophylaxis of receiving or having received or preparing to receive (e.g., later in the same day, the next day, or at 2, 3, 4, 5, 6, 7, 10, within 14 or 21 days) of antibiotic treatment or diarrhea and/or constipation in individuals who are or have had bacterial gastroenteritis. Antibiotic therapy and bacterial gastroenteritis are associated with changes in gut microflora that may precede diarrhea and/or constipation and may be prevented by the compositions of the invention. Compositions of the invention may be administered simultaneously, separately or sequentially with antibiotic therapy. For example, compositions of the invention can be administered concurrently with antibiotic therapy. In preferred embodiments, treatment with a composition of the invention reduces diarrhea and/or constipation. Preventing or preventing diarrhea and/or constipation can mean, for example, alleviating the severity of symptoms or reducing the frequency of exacerbations or range of triggering events that are problematic for the patient. In certain embodiments, compositions of the invention are used to treat or prevent diseases associated with Enterobacteriaceae infections (eg, E. coli infections). In certain embodiments, compositions of the invention are used to treat or prevent diarrhea, gastroenteritis, urinary tract infection, or neonatal meningitis. In these embodiments, the Enterobacteriaceae can be a pathogenic strain. In certain embodiments, compositions of the invention are used to treat or prevent diseases associated with increased concentrations of Enterobacteriaceae (eg, E. coli). In certain embodiments, compositions of the invention are used to treat or prevent diarrhea, gastroenteritis, urinary tract infection, or neonatal meningitis. In these embodiments, the Enterobacteriaceae can be commensal or non-pathogenic strains. In a preferred embodiment, the composition of the present invention is used to reduce the concentration of Enterobacteriaceae, preferably Escherichia coli, in the gastrointestinal tract, for the treatment or prevention of diseases associated with increased concentrations of Enterobacteriaceae (e.g. IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhea, gastroenteritis, urinary tract infection, or neonatal meningitis). Enterobacteriaceae and especially Escherichia coli are known to potentially trigger or be known to exacerbate Crohn's disease and ulcerative colitis [22-24], so the effects demonstrated in the examples of the composition of the present invention may be beneficial in the treatment of these symptoms. In certain embodiments, compositions of the invention are used to treat or prevent IBS, Crohn's disease, ulcerative colitis, functional dyspepsia, diarrhea, gastroenteritis, Urinary tract infection or neonatal meningitis. Mode of Administration Preferably, the compositions of the invention are intended to be administered to the gastrointestinal tract to enable delivery and/or partial or complete colonization of the bacterial strains of the invention into the intestine. Typically, compositions of the invention are administered orally, but they may be administered rectally, intranasally, or via buccal or sublingual routes. In certain embodiments, compositions of the present invention may be administered as a foam, spray, or gel. In certain embodiments, compositions of the invention may be administered in the form of suppositories (eg, rectal suppositories), eg, in the form of cocoa tree oil (cocoa butter), synthetic hard fats (eg, suppocire, witepsol), )), glycerin-gelatin, polyethylene glycol or soap-glycerin compositions. In certain embodiments, via a tube (e.g., nasogastric, orogastric, gastric, jejunostomy (J-tube), percutaneous endoscopic gastrostomy (PEG) tube) or hole (e.g., into stomach, chest wall opening of the jejunum, and other suitable access openings) to administer the compositions of the present invention to the gastrointestinal tract. Compositions of the invention may be administered once, or they may be administered sequentially as part of a treatment regimen. In certain embodiments, compositions of the invention are administered daily. The examples demonstrate that administration provides successful colonization and clinical benefit in the treatment of diarrhea and/or constipation. In certain embodiments, compositions of the invention are administered on a regular basis (e.g., every day, every two days, or every week) for an extended period of time, such as at least one week, two weeks, one month, two months, six months, or one year . The examples demonstrate that BH administration does not permanently colonize the intestine, so regular administration for extended periods of time may provide greater therapeutic benefit. In some embodiments, a composition of the invention is administered for 7 days, 14 days, 16 days, 21 days, or 28 days or for no more than 7 days, 14 days, 16 days, 21 days, or 28 days. For example, in some embodiments, a composition of the invention is administered for 16 days. In certain embodiments of the invention, treatment of the invention is accompanied by an assessment of the patient's gut microflora. If delivery and/or partial or complete colonization of the strain of the invention is not achieved such that efficacy is not observed, treatment may be repeated, or if successful delivery and/or partial or complete colonization is achieved and efficacy is observed, treatment may be discontinued . In certain embodiments, compositions of the invention may be administered to a pregnant animal (eg, a mammal, eg, a human) to prevent diarrhea and/or constipation in utero and/or in a postnatal child. Compositions of the invention may be administered to patients who have been diagnosed with or have been identified as being at risk of diarrhea and/or constipation or a disease or condition associated with diarrhea and/or constipation. Compositions may also be administered as a prophylactic measure to prevent diarrhea and/or constipation in healthy patients. Compositions of the invention can be administered to patients identified as having abnormal gut microflora. For example, a patient may have reduced or absent colonization of Blautia and in particular hydrogenotrophic Blautia, Blautia faecalis or Brautia weikla-Broutia . Compositions of the invention may be administered in the form of a food product (eg, a nutritional supplement). Typically, the compositions of the invention are used in the treatment of humans, but they may be used in the treatment of animals including monogastric mammals, such as poultry, pigs, cats, dogs, horses or rabbits. The compositions of the present invention are useful for enhancing the growth and performance of animals. If administered to animals, oral gavage can be used. In some embodiments, the system to which the composition is administered is an adult human. In some embodiments, the individual system to which the composition is administered is an infant human. Compositions Typically, compositions of the invention comprise bacteria. In a preferred embodiment of the present invention, the composition is prepared in a lyophilized form. For example, compositions of the invention may comprise granules or gelatin capsules, eg hard gelatin capsules, containing the bacterial strains of the invention. Preferably, the compositions of the invention comprise lyophilized bacteria. Freeze-drying of bacteria is a well-established procedure and relevant guidelines are available, for example, from refs [25-27]. Lyophilizate compositions can be especially effective. In a preferred embodiment, the composition of the present invention comprises freeze-dried bacteria and is used to treat diarrhea and/or constipation associated with IBS. Alternatively, the compositions of the invention may comprise live active bacterial cultures. The examples demonstrate that the cultures of the bacteria of the invention are therapeutically effective. In some embodiments, the bacterial strains in the compositions of the invention have not been inactivated, eg, have not been heat-inactivated. In some embodiments, the bacterial strains in the compositions of the invention have not been killed, eg, have not been heat killed. In some embodiments, the bacterial strains in the compositions of the invention have not been attenuated, eg, have not been heat attenuated. For example, in some embodiments, the bacterial strains in the compositions of the invention have not been killed, inactivated and/or attenuated. For example, in some embodiments, the bacterial strains in the compositions of the invention are live. For example, in some embodiments, bacterial strains in the compositions of the present invention can be grown. For example, in some embodiments, the bacterial strains in the compositions of the invention are capable of partially or fully colonizing the intestine. For example, in some embodiments, the bacterial strains in the compositions of the invention are vegetative and capable of partially or fully colonizing the intestine. In some embodiments, the composition comprises a mixture of live and killed bacterial strains. In preferred embodiments, the compositions of the invention are encapsulated to enable delivery of the bacterial strains to the intestine. Encapsulation can protect the composition from degradation until delivery at the target site via, for example, disruption using chemical or physical stimuli such as pressure, enzymatic activity, or physical disintegration, which can be triggered by a pH change. Any suitable encapsulation method can be used. Exemplary encapsulation techniques include encapsulation within porous matrices, attachment or adsorption on the surface of solid carriers, self-aggregation by flocculation or using cross-linking agents, and mechanical containment within microporous membranes or microcapsules. Guidance on encapsulation that can be used to prepare compositions of the invention can be obtained, for example, from refs [28-29]. The compositions can be administered orally and can be in the form of tablets, capsules or powders. Encapsulated products are better because Blautia is anaerobic. Other ingredients such as vitamin C may be included as oxygen scavengers and substrates of prebiotics for improved in vivo delivery and/or partial or complete colonization and growth development. Alternatively, the probiotic composition of the present invention may be administered orally as a food or encapsulated product, such as an emulsion or whey based fermented dairy product, or as a medicinal product. Compositions may be formulated as probiotics. Compositions of the invention include a therapeutically effective amount of a bacterial strain of the invention. A therapeutically effective amount of the bacterial strain is sufficient to exert a beneficial effect on the patient. A therapeutically effective amount of the bacterial strain may be sufficient to allow delivery to and/or partial or complete colonization of the intestine of a patient. For example, a suitable daily dose of bacteria for an adult human may be about 1 x ¹⁰³ to about 1 x ¹⁰¹¹ colony forming units (CFU); for example about 1 x ¹⁰⁷ to about 1 x ¹⁰¹⁰ CFU; In one example about 1 x 10 ⁶ to about 1 x 10 ¹⁰ CFU; in another example about 1 x 10 ⁷ to about 1 x 10 ¹¹ CFU; in another example about 1 x 10 ⁸ to about 1 x 10 ¹⁰ CFU; in another example from about 1 x ¹⁰⁸ to about 1 x ¹⁰¹¹ CFU. In certain embodiments, the dose of bacteria is at least 10 ⁹ cells/day, eg, at least 10 ¹⁰ , at least 10 ¹¹ , or at least 10 ¹² cells/day. In certain embodiments, the composition is present in an amount of about 1×10 ⁶ to about 1×10 ¹¹ CFU/g (eg, about 1×10 ⁸ to about 1×10 ¹⁰ CFU/g), relative to the weight of the composition Contains bacterial strains. Doses may be, for example, 1 g, 3 g, 5 g and 10 g. Typically, a probiotic, such as a composition of the invention, is optionally combined with at least one suitable prebiotic compound. Prebiotic compounds are generally non-digestible carbohydrates (such as oligo- or polysaccharides or sugar alcohols), which are not degraded or absorbed in the upper digestive tract. Known prebiotics include commercial products such as inulin and trans-galacto-oligosaccharides. In certain embodiments, the probiotic composition of the present invention includes a prebiotic compound in an amount of about 1% to about 30% by weight, such as 5% to 20% by weight, relative to the total weight of the composition. The carbohydrate may be selected from the group consisting of: fructo-oligosaccharides (or FOS), short chain fructo-oligosaccharides, inulin, isomaltose-oligosaccharides, pectin, xylose-oligosaccharides (or XOS), chitin Glycan-Oligosaccharides (or COS), β-glucan, modified and resistant starch with acacia gum, polydextrose, D-tagatose, acacia fiber, acacia, oat and citrus fiber. In one aspect, prebiotics are short-chain fructo-oligosaccharides (shown below as FOS-cc for simplicity); these FOSs-cc are not digestible carbohydrates, which are usually obtained by conversion of beet sugar And includes a sucrose molecule bonded by three glucose molecules. The compositions of the present invention may comprise pharmaceutically acceptable excipients or carriers. Examples of such suitable excipients can be found in reference [30]. Acceptable carriers or diluents for therapeutic applications are well known in the medical art and are described, for example, in ref. [31]. Examples of suitable carriers include lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol, sorbitol, and the like. Examples of suitable diluents include ethanol, glycerol and water. The choice of pharmaceutical carrier, excipient or diluent can be chosen with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical composition may comprise any suitable binder, lubricant, suspending agent, coating agent, solubilizer as or in addition to a carrier, excipient or diluent , lubricants, suspending agents, coating agents, solubilizers. Examples of suitable binders include starch, gelatin, natural sugars such as dextrose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth, or sodium alginate ), carboxymethylcellulose and polyethylene glycol. Examples of suitable lubricants include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Preservatives, stabilizers, dyes and even flavoring agents can be provided in pharmaceutical compositions. Examples of preservatives include sodium benzoate, sorbic acid, cysteine, and parabens, for example, and in some embodiments, the preservative is selected from sodium benzoate, sorbic acid, and parabens . Antioxidants and suspending agents may also be used. Another example of a suitable carrier is sucrose. Another example of a preservative is cysteine. Compositions of the invention may be formulated as food products. For example, food products may provide nutritional benefits, such as in the form of nutritional supplements, in addition to the therapeutic effects of the present invention. Similarly, food products can be formulated to enhance the taste of the compositions of the invention or to make the compositions more attractive for consumption by resembling commonly used food items rather than pharmaceutical compositions. In certain embodiments, compositions of the present invention are formulated as emulsion-based products. The term "emulsion-based product" means any liquid or semi-solid product based on emulsion or whey with different fat content. Emulsion-based products can be, for example, cow's milk, goat's milk, sheep's milk, skim emulsion, whole milk, emulsion reconstituted from milk powder and whey without any treatment or processed products (such as yoghurt, coagulated emulsion, curd , yogurt, sour whole milk, buttermilk and other yogurt products). Another important group includes emulsion drinks, such as whey drinks, fermented milk, condensed milk, milk drinks for infants or young children; flavored milk, ice cream; dairy foods, such as sweets. In some embodiments, compositions of the present invention comprise one or more bacterial strains of the genus Blautia and are free of bacteria from any other genus, or contain only trace or biologically irrelevant amounts of bacteria from another genus. bacteria. In certain embodiments, compositions of the invention contain a single bacterial strain or species and are free of any other bacterial strains or species. These compositions may contain only trace or biologically irrelevant amounts of other bacterial strains or species. These compositions may be cultures that are substantially free of other species of organisms. In some embodiments, such compositions may be lyophilizates substantially free of other organism species. In certain embodiments, compositions of the present invention comprise one or more bacterial strains of the genus Blautia (e.g., hydrogenotrophic Blautia) and no other bacterial genera, or they comprise only trace amounts or A biologically irrelevant quantity of bacteria from another genus. In certain embodiments, compositions of the invention comprise a single species of Blautia species (eg, hydrogenotrophic Blautia species) and no other bacterial species, or they comprise only trace or biologically irrelevant amounts of Bacteria from another species. In certain embodiments, compositions of the present invention comprise a single strain of Blautia bacterium (e.g., hydrogenotrophic Blautia spp.) and are free of any other bacterial strain or species, or they contain only trace amounts or biologically unrelated Quantity of bacteria from another strain or species. In some embodiments, compositions of the invention comprise more than one strain or species of bacteria. For example, in some embodiments, compositions of the invention comprise more than one strain from the same species (e.g., greater than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40 or 45 strains) and optionally no bacteria from any other species. In some embodiments, compositions of the invention comprise less than 50 strains from within the same species (e.g., less than 45, 40, 35, 30, 25, 20, 15, 12, 10, 9, 8, 7, 6, 5 , 4 or 3 strains) and optionally does not contain bacteria from any other species. In some embodiments, the compositions of the present invention comprise 1-40, 1-30, 1-20, 1-19, 1-18, 1-15, 1-10, 1-9, 1-8, 1-7 , 1-6, 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6 - 30, 6-15, 16-25 or 31-50 strains from within the same species and optionally no bacteria from any other species. In some embodiments, compositions of the invention comprise more than one species from the same genus (e.g., greater than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 17, 20, 23, 25, 30, 35 or 40 species), and optionally no bacteria from any other genera. In some embodiments, compositions of the invention comprise less than 50 species from the same genus (e.g., less than 50, 45, 40, 35, 30, 25, 20, 15, 12, 10, 8, 7, 6, 5 , 4 or 3 species), and optionally no bacteria from any other genera. In some embodiments, the compositions of the present invention comprise 1-50, 1-40, 1-30, 1-20, 1-15, 1-10, 1-9, 1-8, 1-7, 1-6 , 1-5, 1-4, 1-3, 1-2, 2-50, 2-40, 2-30, 2-20, 2-15, 2-10, 2-5, 6-30, 6 - 15, 16-25 or 31-50 species from the same genus and optionally no bacteria from any other genus. The present invention includes any combination of the foregoing. In some embodiments, the composition comprises a microbial consortium. For example, in some embodiments, a composition comprises a strain of Blautia bacteria as part of a microbial consortium. For example, in some embodiments, the Blautia bacterial strain is present in combination with one or more (e.g., at least 2, 3, 4, 5, 10, 15, or 20) other bacterial strains from other genera that and other strains can live symbiotically in the intestine in vivo. For example, in some embodiments, the composition comprises a bacterial strain of the hydrogenotrophic Blautia in combination with a bacterial strain from a different genus. In some embodiments, a microbial consortium comprises two or more bacterial strains obtained from a stool sample of a single organism (eg, a human). In some embodiments, microbial consortia are not found together in nature. For example, in some embodiments, the microbial consortium comprises bacterial strains obtained from stool samples of at least two different organisms. In some embodiments, two different organisms are from the same species, such as two different humans. In some embodiments, two different organisms are infant human and adult human. In some embodiments, two different organisms are human and non-human mammal. In some embodiments, the composition of the invention additionally comprises a bacterial strain having the same safety and therapeutic efficacy properties as the hydrogenotrophic Blautia strain deposited under accession number DSM 10507/14294, but which is not registered under Deposited under DSM 10507/14294 a hydrogenotrophic Brautia strain or a non-hydrogenotrophic Brautia strain or a non-Broutia strain. In some embodiments where the compositions of the invention comprise more than one bacterial strain, species or genus, the individual bacterial strains, species or genus may be administered separately, simultaneously or sequentially. For example, a composition may comprise all of more than one bacterial strain, species or genus, or the bacterial strains, species or genera may be stored separately and administered separately, simultaneously or sequentially. In some embodiments, more than one bacterial strain, species or genus is stored separately but mixed together prior to use. In some embodiments, the bacterial strains used in the present invention are obtained from human adult feces. In some embodiments where the compositions of the invention comprise more than one bacterial strain, all bacterial strains are obtained from human adult feces, or other bacterial strains, if present, are present in only trace amounts. Bacteria may be cultured after being obtained from human adult faeces and used in the compositions of the invention. In some embodiments, one or more strains of Blautia bacteria are the only therapeutically active agents in compositions of the invention. In some embodiments, the bacterial strain in the composition is the only therapeutically active agent in the composition of the invention. Compositions for use in the present invention may or may not require marketing approval. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is lyophilized. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is spray-dried. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein it is live. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein it can be grown. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein it is capable of partially or completely colonizing the intestine. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is freeze-dried or spray-dried and wherein it is vegetative and capable of partially or fully colonizing the intestine. In some instances, lyophilized or spray-dried bacterial strains are reconstituted prior to administration. In some cases, reconstitution is by use of the diluents described herein. The compositions of the present invention may comprise a pharmaceutically acceptable excipient, diluent or carrier. In some embodiments, the present invention provides a pharmaceutical composition, which comprises: the bacterial strain of the present invention ; and a pharmaceutically acceptable excipient, carrier or diluent; wherein the amount of the bacterial strain is sufficient for administration as needed and wherein the condition is diarrhea and/or constipation, such as diarrhea and/or constipation associated with Crohn's disease, ulcerative colitis or more preferably IBS. In some embodiments, the present invention provides the above pharmaceutical composition, wherein the amount of the bacterial strain is about 1×10 ³ to about 1×10 ¹¹ colony forming units/gram weight of the composition. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the composition is administered at a dose of 1 g, 3 g, 5 g, or 10 g. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the composition is administered by a method selected from the group consisting of oral, rectal, subcutaneous, nasal, buccal, and sublingual. In certain embodiments, the present invention provides the above pharmaceutical composition, which comprises a carrier selected from the group consisting of lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol and sorbitol. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, which comprises a diluent selected from the group consisting of ethanol, glycerin and water. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition comprising an excipient selected from the group consisting of starch, gelatin, glucose, anhydrous lactose, free-flowing lactose, beta-lactose, corn sweetener, Gum Arabic, Gum Tragacanth, Sodium Alginate, Carboxymethylcellulose, Macrogol, Sodium Oleate, Sodium Stearate, Magnesium Stearate, Sodium Benzoate, Sodium Acetate and Sodium Chloride. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, which further comprises at least one of a preservative, an antioxidant, and a stabilizer. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, which comprises a preservative selected from the group consisting of sodium benzoate, sorbic acid, and parabens. In certain embodiments, there is provided a pharmaceutical composition of the present invention, wherein the composition does not contain any minerals, or more specifically any metal having an atomic number greater than 33, for example, wherein the composition does not contain Any mineral from the group consisting of selenium, molybdenum, tungsten, selenium compounds, molybdenum compounds and tungsten compounds. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein the bacterial strain is lyophilized. In certain embodiments, the present invention provides the aforementioned pharmaceutical composition, wherein when the composition is stored in a sealed container at about 4°C or about 25°C and the container is placed in an atmosphere with a relative humidity of 50%, at least 80% of the bacterial strains (as measured in colony forming units) are retained after a period of at least about 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years, or 3 years. In some embodiments, a composition of the invention is provided in a sealed container comprising a composition as described herein. In some embodiments, the sealed container is a sachet or bottle. In some embodiments, a composition of the invention is provided in a syringe comprising a composition as described herein. In some embodiments, compositions of the invention may be provided as pharmaceutical formulations. For example, the composition may be provided as a tablet or capsule. In some embodiments, the capsule is a gelatin capsule ("gel-cap"). In some embodiments, compositions of the invention are administered orally. Oral administration may involve swallowing (to allow the compound to enter the gastrointestinal tract) and/or buccal, lingual, or sublingual administration (whereby the compound enters the bloodstream directly from the mouth). Pharmaceutical formulations suitable for oral administration include solid plugs, solid particulates, semi-solids and liquids (including heterogeneous or dispersed systems), such as lozenges; soft or hard capsules containing multi- or nanoparticles, liquids (such as aqueous solutions), emulsions or powders; lozenges (including fill liquids); chewables; gels; rapidly dispersing dosage forms; films; vaginal lozenges; sprays; and buccal or mucoadhesive patches. In some embodiments, the pharmaceutical formulation is an enteric formulation, ie, a gastroresistant formulation (eg, resistant to gastric pH) suitable for delivery of a composition of the invention to the intestine by oral administration. Enteric formulations are particularly useful when the bacteria or another component of the composition is acid sensitive (eg, readily degrades under gastric conditions). In some embodiments, enteric formulations comprise an enteric coating. In some embodiments, the formulation is an enteric coated dosage form. For example, the formulation may be an enteric-coated tablet or an enteric-coated capsule or the like. The enteric coating may be a customary enteric coating, eg, of tablets, capsules or the like for oral delivery. The formulation may comprise a film coating, eg a film layer of an enteric polymer such as an acid insoluble polymer. In some embodiments, enteric formulations are enteric in nature, eg, gastroresistant and do not require enteric coatings. Accordingly, in some embodiments, the formulation is an enteric formulation that does not comprise an enteric coating. In some embodiments, the formulation is a capsule made from thermally gelling material. In some embodiments, the thermosetting material is a cellulosic material such as methylcellulose, hydroxymethylcellulose, or hydroxypropylmethylcellulose (HPMC). In some embodiments, the capsule comprises a shell that is free of any film-forming polymer. In some embodiments, the capsule comprises a shell and the shell comprises hydroxypropylmethylcellulose and does not comprise any film-forming polymer (see eg [32]). In some embodiments, the formulations are essentially enteric-coated capsules (eg, Vcaps® from Capsugel). In some embodiments, the formulation is a soft capsule. Soft capsules are capsules that can exist in the capsule shell and have certain elasticity and softness due to the addition of lubricants (such as glycerin, sorbitol, maltitol and polyethylene glycol). Soft capsules can be produced, for example, based on gelatin or starch. Gelatin-based soft capsules are commercially available from various suppliers. Depending on the method of administration (eg, oral or rectal), soft capsules can have various shapes, which can be, for example, round, oval, oblong, or torpedo-shaped. Soft capsules can be produced by customary processes, for example by the Scherer process, the Accogel process or drop or blown processes. Cultivation Methods The bacterial strains used in the present invention can be grown using standard microbiological techniques, as detailed, for example, in refs [33-35]. The solid or liquid medium used for cultivation may be, for example, YCFA agar or YCFA medium. YCFA medium may include (per 100ml, approx.): tyrosine (1.0 g), yeast extract (0.25 g), NaHCO ₃ (0.4 g), cysteine (0.1 g), K ₂ HPO ₄ (0.045 g) , KH ₂ PO ₄ (0.045 g), NaCl (0.09 g), (NH ₄ ) ₂ SO ₄ (0.09 g), MgSO ₄ · 7H ₂ O (0.009 g), CaCl ₂ (0.009 g), resazurin ( 0.1 mg), hemin (1 mg), biotin (1 μg), cobalamin (1 μg), p-aminobenzoic acid (3 μg), folic acid (5 μg), and pyridoxamine (15 μg ). General The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, biochemistry, molecular biology, immunology and pharmacology, known to those skilled in the art. Such techniques are explained fully in the literature. For example, see references [36-43] and so on. The term "comprising" encompasses "comprising" as well as "consisting of", for example, a composition "comprising" X may consist exclusively of X or may include other items such as X+Y. The term "about" in relation to a value x is optional and means, for example, x ± 10%. The word "substantially" does not exclude "completely", for example, a composition that is "substantially free" of Y may be completely free of Y. The word "substantially" can be omitted from the definition of the present invention if necessary. Reference to a percent sequence identity between two nucleotide sequences means that, when aligned, that percent of the nucleotides are identical when the two sequences are aligned. This alignment and percent homology or sequence identity can be determined using software programs known in the art, such as those described in Section 7.7.18 of ref. [44]. Optimal alignments were determined by the Smith-Waterman homology search algorithm using affine gap searching with a gap opening penalty of 12 and a gap extension penalty of 2 for a BLOSUM matrix of 62. The Smith-Waterman homology search algorithm is disclosed in Ref. [45]. A process or method that includes multiple steps may include other steps at the beginning or end of the method, or may include other intervening steps, unless specifically stated otherwise. Likewise, steps may be combined, omitted, or performed in an alternate order, as appropriate. Various embodiments of the invention are described herein. It should be appreciated that specified features in each embodiment can be combined with other specified features to provide other embodiments. In particular, embodiments highlighted herein as suitable, typical or preferred may be combined with each other (except where they are mutually exclusive). Example 1 of a model for implementing the present invention - Changes in symptoms of patients during a phase I clinical trial A phase I clinical trial was implemented in which the hydrogenotrophic Brautia spp. The strain deposited under DSM 14294) was administered to human patients with irritable bowel syndrome (IBS). Brautica was administered to patients during the dosing period (Days 1-16) with a washout period of Days 19-23. Broutica was found to be safe and well tolerated. Four symptoms were monitored, two of which were diarrhea and constipation. The study records patients experiencing improvement, no change, or worsening of each of these symptoms. The results from patients administered bruutica were compared to those obtained with patients administered placebo. Symptoms were monitored at three time points: Day 1, Day 15/16 and at the end of the study. The results are shown in Figures 1 and 2. When comparing patients' reported symptoms on Day 16 to baseline from Day 1, 82% of the 17 IBS patients who received brutica reported improved symptoms (Figure 1). Improvement in symptoms, both of which are diarrhea and constipation, supports the use of bruutica for the treatment or prevention of diarrhea and/or constipation. 50% of patients receiving placebo reported improved symptoms (Figure 1). High placebo response rates are an established phenomenon in IBS clinical research. Xifaxan was recently approved for the treatment of IBS based on minimal improvement over placebo (see: http://www.accessdata.fda.gov/spl/data/5ab6fceb-4d22-4480-81fc-8bc28c16770d/5ab6fceb -4d22-4480-81fc-8bc28c16770d.xml ). Based on the teachings presented herein, symptoms are expected to worsen at the completion of the study (Days 19-23) compared to symptoms present at the completion of dosing (Day 16). This exacerbation of symptoms was seen in Phase I clinical trials: 41% of IBS patients reported exacerbation of symptoms after discontinuation of bruutica (Figure 2). The exacerbation of symptoms (both of which are diarrhea and constipation) following discontinuation of the administration of bruutica also supports the use of bruutica for the treatment or prevention of diarrhea and/or constipation. Example 2 - Hydrogen Breath Test Results Breath hydrogen concentration is a biomarker of Brautik activity - MoA is involved in the metabolism of endogenous _H2 to produce acetate. Human subjects were administered lactulose and hydrogen ( _H2 ) concentrations (Cmax) were sampled at 4 time points: Day 1, Day 2, Day 15, and Day 16. Converts hydrogen uncorrected results to hydrogen corrected results. Some patients were excluded from the analysis. There were three reasons why individuals could not be included in the hydrogen breath test analysis: 1) they produced a CMAX hydrogen breath test result of <20 on one of the 4 sampling dates and were therefore considered non-responsive to the test; 2) they had Is a methane producer (thought to produce more methane than hydrogen in the breath test), which affects the hydrogen reaction; and/or 3) obtains an outlier (232 ppm) in the hydrogen breath test. Individuals 3.12 (Brautica), 3.24 (Brautica), 4.07 (Brautica) were excluded as non-responders. Subjects 3.03 (Blautica) and 3.08 (Placebo) were excluded as methane producers (4.07 mentioned as excluded above was also a methane producer). Subject 4.09 (placebo) was excluded due to outliers. The results from the calibrated hydrogen analysis at the end of the dosing period (Day 15/16) were compared with their results from the baseline (Day 1/2). Ten of 12 patients (83%) who received bruutica had a decrease in hydrogen concentration during this time period (Figures 3a and 3c). In contrast, 3 of 6 patients (50%) receiving placebo had reduced hydrogen concentrations (Figures 3b and 3c). These percentages were similar to the percentages of patients exhibiting improved symptoms following bruutica treatment or administration of placebo. Figure 4 shows the unadjusted and hydrogen corrected results for the Brautica (Verum) treatment group and the statistical analysis of these results. The mean values of uncorrected and corrected _H2 were found to differ between day 1 and day 15. After 13.5 days of treatment, a statistically significant (p<0.05) decrease in _H2 in the Cmax breath test was detected after lactulose challenge. In contrast, for the placebo group, the mean values at day 1 and day 15 were found to be equivalent (p > 0.05) ( FIG. 5 ). Thus, for both unadjusted and corrected hydrogen results, the treatment group (also referred to as the VERUM group) had a mean decrease between Day 1 and Day 15, while the placebo group mean had decreased between Day 1 and Day 15. Equivalence between day 15 and day 15 (Figure 6). Example 3 - Stability Test A composition described herein containing at least one bacterial strain described herein was stored in a sealed container at 25°C or 4°C and the container was placed at 30%, 40%, 50%, 60% , 70%, 75%, 80%, 90% or 95% relative humidity atmosphere. After 1 month, 2 months, 3 months, 6 months, 1 year, 1.5 years, 2 years, 2.5 years or 3 years, at least 50%, 60%, 70%, 80% or 90% of bacteria Strains should be retained as measured in colony forming units determined by standard protocols. Sequence SEQ ID NO: 1 (Broutia faecalis strain GAM6-1 16S ribosomal RNA gene, partial sequence - HM626177) 1 tgcaagtcga gcgaagcgct tacgacagaa ccttcggggg aagatgtaag ggactgagcg 61 gcggacgggt gagtaacgcg tgggtaacct gcctcataca gggggataac agttggaaac 121 ggctgctaat accgcataag cgcacggtat cgcatgatac agtgtgaaaa actccggtgg 181 tatgagatgg acccgcgtct gattagctag ttggaggggt aacggcccac caaggcgacg 241 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc 301 ctacgggagg cagcagtgggg gaatattgca caatggggga aaccctgat g cagcgacgcc 361 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaaga aaatgacggt 421 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca 481 agcgttatcc ggatttactg ggtgtaaagg gagcgta gac ggaagagcaa gtctgatgtg 541 aaaggctggg gcttaaccccc aggactgcat tggaaactgt ttttcttgag tgccggagag 601 gtaagcggaa ttcctagtgt agcggtgaaa tgcgtagata ttaggaggaa caccagtggc 661 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg 721 attagatacc ctggtagtcc acgccgtaaa cgatgaatac taggtgt tgg ggagcaaagc 781 tcttcggtgc cgcagcaaac gcaataagta ttccacctgg ggagtacgtt cgcaagaatg 841 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag 901 caacgcgaag aaccttacca agtcttgaca tc gatctgac cggttcgtaa tggaaccttt 961 ccttcgggac agagaagaca ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt 1021 gggttaagtc ccgcaacgag cgcaacccct atcctcagta gccagcaggt gaagctgggc 1081 actctgtgga gactgccagg gataacctgg aggaaggcgg ggacgacgtc aaatcatcat 1141 gccccttatg atttgggcta cacacgtgct acaatggcgt aaacaaaggg aagcgagcc c 1201 gcgaggggga gcaaatccca aaaataacgt cccagttcgg actgcagtct gcaactcgac 1261 tgcacgaagc tggaatcgct agtaatcgcg aatcagaatg tcgcggtgaa tacgttcccg 1321 ggtcttgtac acaccgcccg tcacaccatg ggag tcagta acgcccgaag tc SEQ ID NO:2 (Weikla-bu Lauteria strain WAL 14507 16S ribosomal RNA gene, partial sequence - EF036467) 1 21 tgctaatacc gcataagcgc acagagctgc atggctcagt gtgaaaaact ccggtggtat 181 aagatggacc cgcgttggat tagcttgttg gtggggtaac ggccccaccaa ggcgacgatc 241 catagccggc ctgagagggt gaacggccac attgggactg agacacggcc cagactccta 301 cgggaggcag cagtggggaa tattgcacaa tgggggaaac cctgatgcag cgacgccgcg 361 tgaaggaaga agtatctcgg tatgtaaact tctatcagca gggaagatag tgacggtacc 421 tgactaagaa gccccggcta actac gtgcc agcagccgcg gtaatacgta gggggcaagc 481 gttatccgga tttactgggt gtaaagggag cgtagacggt gtggcaagtc tgatgtgaaa 541 ggcatgggct caacctgtgg actgcattgg aaactgtcat acttgagtgc cggaggggta 601 agcggaatt c ctagtgtagc ggtgaaatgc gtagatatta ggaggaacac cagtggcgaa 661 ggcggcttac tggacggtaa ctgacgttga ggctcgaaag cgtggggagc aaacaggatt 721 agataccctg gtagtccacg ccgtaaacga tgaataacta ggtgtcgggt ggcaaagcca 781 ttcggtgccg tcgcaaacgc agtaagtatt ccacctgggg agtacgttcg caagaatgaa 841 actcaaagga attgacgggg acccgcacaa gcggtggagc atgtggttta attcgaagca 901 acgcgaagaa ccttaccaag tcttgacatc cgcctgaccg atccttaacc ggatctttcc 961 ttcgggacag gcgagacagg tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg 1021 gttaagtccc gcaacgagcg caacccctat cctcagtagc cagcatttaa ggtgggcact 1081 ctggggagac tgccagggat aacctggagg aaggcgggga tgacgtcaaa tcatcatgcc 1141 ccttatgatt tgggctacac acgtgctaca atggcgtaaa caaagggaag cgagattgtg 1201 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac 1261 acgaagctgg aatcgctagt aatcgcggat cagaatgccg cggtgaatac gttcccgggt 1321 cttgtacaca ccgcccgtca caccatggga gtcagtaacg cccgaagtca gtgacctaac 1381 tgcaaagaag gagctgccga aggcgggacc gatgactggg gtgaagtcgt aacaaggt SEQ ID NO:3 (Dung Heap Braut bacteria strain 830 consensus 16S rRNA sequence) TTTKGTCTGGCTCAGGATGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAGCGAAGCGCTTACGACAGAACCTTCGGGGGAAGATGTAAGGGACTGAGCGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTCATACAGGGGGATAACAGTTGGAAACGGCTGCTAATACCGCATAA GCGCACAGTATCGCATGATACAGTGTGAAAAACTCCGGTGGTATGAGATGGACCCGCGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATG CAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGGGAAGAAAATGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGGGCTTAACCCAGGACTGC ATTGGAAACTGTTTTTCTTGAGTGCCGGAGAGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTTGGGGAGCAAAG CTCTTCGGTGCCGCAGCAAACGCAATAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCGATCTGACCGGTTCGTAATGGAACCTTTCCTTCGGGACAGAGAAGACAGGTGGTGCATGGTTGTCGT CAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCGTCAGTAGCCAGCAGGTAAAGCTGGGCACTCTGAGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGACGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGCCCGCGAGGGGGAGC AAATCCCAAAAATAACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGAAGCTGGAATCGCTAGTAATCGCGAATCAGAATGTCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCCAACCTTAGGGAGGGAGCTGCCGAAGGCGGGATTGATAACTGGGGTGAAG TAGGGGGT SEQ ID NO: 4 (Consensus 16S rRNA sequence of Brautia weiclae strain MRX008) TTCATTGAGACTTCGGTGGATTTAGATTTCTATTTCTAGTGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTTATACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGCATAAGCGCACAGAGCTGCATGGCTCAGT GTGAAAAACTCCGGTGGTATAAGATGGACCCGCGTTGGATTAGCTTGTTGGTGGGGTAACGGCCCACCAAGGCGACGATCCATAGCCGGCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATATTGCACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAG GAAGAAGTATCTCGGTATGTAAACTTCTATCAGCAGCAGGGAAGATAGTGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGGGGGCAAGCGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTGTGGCAAGTCTGATGTGAAAGGCATGGGCTCAACCTGTGGACTGCATTGGAAACTGTCATAC TTGAGTGCCGGAGGGGTAAGCGGAATTCCTAGTGTAGCGGTGAAATGCGTAGATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGAAAGCGTGGGGAGCAAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTCNGGGGAGCATGGCTCTTCGGTGCCG TCGCAAACGCAGTAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAGGAATTGACGGGGACCCGCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAACCTTACCAAGTCTTGACATCCGCCTGACCGATCCTTAACCGGATCTTTCCTTCGGGACAGGCGAGACAGGTGGTGCATGGTTGTCGTCAGCTCGTGTCGT GAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCCTATCCTCAGTAGCCAGCATTTAAGGTGGGCACTCTGGGGAGACTGCCAGGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATCATGCCCCTTATGATTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGGAAGCGAGATCGTGAGATGGAGCAAATCCCAAAATAAC GTCCCAGTTCGGACTGTAGTCTGCAACCCGACTACACGAAGCTGGAATCGCTAGTAATCGCGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCACACCATGGGAGTCAGTAACGCCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA 6S ribosomal RNA Gene, partial sequence - X95624.1) 1 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatag agaacggaga 61 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tgggtaacct 121 gccctataca gggggataac agtta gaaat gactgctaat accgcataag cgcacagctt 181 cgcatgaagc ggtgtgaaaa actgaggtgg tataggatgg acccgcgttg gattagctag 241 ttggtgaggt aacggcccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc 301 cacattggga ct gagaacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 361 caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct cggtatgtaa 421 acttctatca gcagggaaga aagtgacggt acctgactaa gaagccccgg ctaattacgt 481 gccagcagcc gcggtaatac gtaaggggca agcgttatcc ggatttactg ggtgtaaagg 541 gagcgtagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 601 tggaaactgt cagacttgag tgccggagag gcaagcggaa ttcctagtgt agcggtgaaa 661 tgcgtagata ttaggaggaa ca ccagtggc gaaggcggcc tgctggacgg taactgacgt 721 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 781 cgatgaatac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaaac gcaataagta 841 ttcccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 901 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaac cttacc aaatcttgac 961 atccctctga ccgggaagta atgttccctt ttcttcggaa cagaggagac aggtggtgca 1021 tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1081 tattcttagt agccagcagg t agagctggg cactctaggg agactgccag ggataacctg 1141 gaggaaggtg gggatgacgt caaatcatca tgccccttat gatttgggct acacacgtgc 1201 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1261 tctcagttcg gattgtagtc tgcaactcga ctacatgaag ctggaatcgc tagtaatcgc 1321 gaatcagaat gtcgcggtga atacgttccc gggtcttg ta cacaccgccc gtcacaccat 1381 gggagtcagt aacgcccgaa gtcagtgacc caaccnaaag gagggagctg ccgaaggtgg 1441 gactgataac tggggtga Reference [1] Spor et al. (2011) Nat Rev Microbiol . 9(4): 279-90. [2] Eckburg et al. (2005) Science . 10;308(5728):1635-8. [3] Tap et al. (2009) Environ Microbiol, 11(10):2574-84 [4] Macpherson et al. (2001) Microbes Infect . 3(12):1021-35 [5] Macpherson et al. (2002) Cell Mol Life Sci. 59(12):2088-96. [6] Mazmanian et al. (2005) Cell 15 ;122(1):107-18. [7] Frank et al. (2007) PNAS 104(34):13780-5. [8] Scanlan et al. (2006) J Clin Microbiol . 44(11):3980-8 [9] Kang et al. (2010) Inflamm Bowel Dis . 16(12):2034-42. [10] Machiels et al. (2013) Gut . 63(8):1275-83. [11] Lopetuso et al. ( 2013), Gut Pathogens, 5: 23 [12] WO 2013/050792 [13] WO 03/046580 [14] WO 2013/008039 [15] WO 2014/167338 [16] Lee and Lee (2014) World J Gastroenterol. 20(27): 8886-8897. [17] Liu et al. (2008) Int J Syst Evol Microbiol 58, 1896–1902. [18] Bernalier et al. (1996) Arch. Microbiol. 166 (3), 176-183 [19] Park et al. (2012) Int J Syst Evol Microbiol. 62(Pt 4):776-9. [20] Masco et al. (2003) Systematic and Applied Microbiology, 26:557-563. [21] Srůtková et al. (2011) J. Microbiol. Methods , 87(1):10-6. [22] Darfeuille-Michaud et al. (2004) Gastroenterology 127(2):412-21. [23] Strus et al. (2015) Cent Eur J Immunol .40(4):420-30. [24] Petersen et al. (2015) Scand J Gastroenterol .;50(10):1199-207. [25] Miyamoto-Shinohara et al. (2008) J. Gen. Appl. Microbiol. , 54, 9–24. [26] Cryopreservation and Freeze-Drying Protocols, edited by Day and McLellan, Humana Press. [27] Leslie et al. (1995) Appl. Environ. Microbiol. 61, 3592 –3597. [28] Mitropoulou et al. (2013) J Nutr Metab . (2013) 716861. [29] Kailasapathy et al. (2002) Curr Issues Intest Microbiol. 3(2):39-48. [30] Handbook of Pharmaceutical Excipients, 2nd Edition (1994), edited by A Wade and PJ Weller [31] Remington's Pharmaceutical Sciences, Mack Publishing Co. (Edited by AR Gennaro, 1985) [32] US 2016/0067188 [33] Handbook of Microbiological Media, Fourth Edition ( 2010) Ronald Atlas, CRC Press. [34] Maintaining Cultures for Biotechnology and Industry (1996) Jennie C. Hunter-Cevera, Academic Press [35] Strobel (2009) Methods Mol Biol . 581:247-61. [36 ] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th Edition, ISBN: 0683306472. [37] Molecular Biology Techniques: An Intensive Laboratory Course , (Edited by Ream et al., 1998, Academic Press). [38] Methods In Enzymology (edited by S. Colowick and N. Kaplan, Academic Press, Inc.) [39] Handbook of Experimental Immunology , Volumes I-IV (edited by DM Weir and CC Blackwell, 1986, Blackwell Scientific Publications) [40] Sambrook et al. (2001) Molecular Cloning: A Laboratory Manual , 3rd edition (Cold Spring Harbor Laboratory Press). [41] Handbook of Surface and Colloidal Chemistry (Birdi, KS edited, CRC Press, 1997) [42] Ausubel et al. (ed. ) (2002) Short protocols in molecular biology , 5th edition (Current Protocols). [43] PCR (Introduction to Biotechniques Series ), 2nd edition (Edited by Newton & Graham, 1997, Springer Verlag) [44] Current Protocols in Molecular Biology (eds. FM Ausubel et al., 1987) Suppl. 30 [45] Smith & Waterman (1981) Adv. Appl. Math. 2: 482-489.

圖 1 ： I期臨床試驗之投藥期(第1-16天)期間之患者症狀變化。圖 2 ： I期臨床試驗之清除期期間之患者症狀變化。圖 3 ：使用布勞替克(Blautix)治療之IBS患者(圖 3a )及使用安慰劑治療之IBS患者(圖 3b )在第1天、第2天、第15天及第16天之氫呼吸測試Cmax結果。圖 3c 係比較第15天及第16天平均值與第1天及第2天平均值間之氫有所降低之布勞替克治療患者百分比與該等時間點間之氫有所降低之安慰劑治療患者百分比的圖形。圖 4a ：布勞替克治療IBS患者在第1天及第15天之氫未校正及氫校正呼吸測試配對數據；圖 4b ：比較布勞替克治療組在第1天及第15天之平均氫未校正呼吸測試結果之圖形；圖 4c ：比較布勞替克治療組在第1天及第15天之平均氫校正呼吸測試結果之圖形。圖 5a ：安慰劑治療IBS患者在第1天及第15天之氫未校正及氫校正呼吸測試配對數據；圖 5b ：比較安慰劑組在第1天及第15天之平均氫未校正呼吸測試結果之圖形；圖 5c ：比較安慰劑組在第1天及第15天之平均氫校正呼吸測試結果之圖形。圖 6 ：比較布勞替克治療組(Verum)及安慰劑組在第1天及第15天之平均氫呼吸測試結果之圖形(圖 6a ：未校正氫；圖 6b ：校正氫)。 Figure 1 : Changes in symptoms of patients during the administration period (days 1-16) of phase I clinical trials. Figure 2 : Changes in patient symptoms during the washout phase of the phase I clinical trial. Figure 3 : Hydrogen respiration on days 1, 2, 15 and 16 in IBS patients treated with Blautix ( Figure 3a ) and in IBS patients treated with placebo ( Figure 3b ) Test Cmax results. Figure 3c compares the percentage of bruutica-treated patients with a decrease in hydrogen between the mean of days 15 and 16 and the mean of days 1 and 2 versus placebo with a decrease in hydrogen between these time points A graph of the percentage of patients treated with a single dose. Figure 4a : paired data of hydrogen uncorrected and hydrogen corrected breath test on day 1 and day 15 of IBS patients treated with Brautica; Figure 4b : comparison of mean Graph of hydrogen uncorrected breath test results; FIG . 4c : Graph comparing mean hydrogen corrected breath test results on day 1 and day 15 of the Blautic treatment group. Figure 5a : Paired hydrogen uncorrected and hydrogen corrected breath test data of placebo-treated IBS patients on day 1 and day 15; Figure 5b : comparison of mean hydrogen uncorrected breath test on day 1 and day 15 of the placebo group Graph of the results; Figure 5c : Graph comparing the mean hydrogen-corrected breath test results of the placebo group on day 1 and day 15. Figure 6 : Graph comparing the mean hydrogen breath test results on days 1 and 15 of the Brautik treatment group (Verum) and the placebo group ( Figure 6a : uncorrected for hydrogen; Figure 6b : corrected for hydrogen).

TW中華民國食品工業發展研究所生物資源保存及研究中心2016/09/20 BCRC 910744； TW中華民國食品工業發展研究所生物資源保存及研究中心2016/09/20 BCRC 910745； GB英國食品工業與海洋細菌菌種保藏中心(National Collections of Industrial, Food and Marine Bacteria；NCIMB) 2015/03/12 NCIMB 42381； GB英國食品工業與海洋細菌菌種保藏中心(National Collections of Industrial, Food and Marine Bacteria；NCIMB) 2015/11/16 NCIMB 42486TW ROC Food Industry Development Institute Biological Resource Conservation and Research Center 2016/09/20 BCRC 910744; TW ROC Food Industry Development Institute Biological Resource Conservation and Research Center 2016/09/20 BCRC 910745; GB UK Food Industry and Marine National Collections of Industrial, Food and Marine Bacteria (NCIMB) 2015/03/12 NCIMB 42381; GB National Collections of Industrial, Food and Marine Bacteria (NCIMB) 2015/11/16 NCIMB 42486

<110> 英商4D製藥有限公司(4D PHARMA PLC) <110> Yingshang 4D Pharmaceutical Co., Ltd. (4D PHARMA PLC)

<120> 包含細菌菌株之組合物 <120> Compositions comprising bacterial strains

<140> TW 106123394 <140> TW 106123394

<141> 2017-03-06 <141> 2017-03-06

<150> GB 1612190.7 <150> GB 1612190.7

<151> 2016-07-13 <151> 2016-07-13

<150> GB 1616016.0 <150> GB 1616016.0

<151> 2016-09-20 <151> 2016-09-20

<150> GB 1616018.6 <150> GB 1616018.6

<151> 2016-09-20 <151> 2016-09-20

<150> GB 1703548.6 <150> GB 1703548.6

<151> 2017-03-06 <151> 2017-03-06

<150> GB 1703552.8 <150> GB 1703552.8

<151> 2017-03-06 <151> 2017-03-06

<160> 5 <160> 5

<170> SeqWin2010,version 1.0 <170> SeqWin2010, version 1.0

<210> 1 <210> 1

<211> 1372 <211> 1372

<212> DNA <212>DNA

<213> 糞堆布勞特氏菌 <213> Brautia faecalis

<400> 1

<400> 1

<210> 2 <210> 2

<211> 1438 <211> 1438

<212> DNA <212>DNA

<213> 魏克拉-布勞特氏菌 <213> Weikla-Broutia

<220> <220>

<221> modified base <221> modified base

<222> 19 <222> 19

<223> 「n」係a、c、g或t <223> "n" means a, c, g or t

<400> 2

<400> 2

<210> 3 <210> 3

<211> 1481 <211> 1481

<212> DNA <212>DNA

<213> 糞堆布勞特氏菌 <213> Brautia faecalis

<220> <220>

<221> modified base <221> modified base

<222> 4 <222> 4

<223> 「k」係g或t <223> "k" means g or t

<400> 3

<400> 3

<210> 4 <210> 4

<211> 1384 <211> 1384

<212> DNA <212>DNA

<213> 魏克拉-布勞特氏菌 <213> Weikla-Broutia

<220> <220>

<221> modified base <221> modified base

<222> 749 <222> 749

<223> 「n」係a、c、g或t <223> "n" means a, c, g or t

<400> 4

<400> 4

<210> 5 <210> 5

<211> 1458 <211> 1458

<212> DNA <212>DNA

<213> 氫營養型布勞特氏菌 <213> Hydrogenotrophic Blautia

<220> <220>

<221> modified base <221> modified base

<222> 1416 <222> 1416

<223> 「n」係a、c、g或t <223> "n" means a, c, g or t

<400> 5

<400> 5

Claims

A species of Blautia hydrogenotrophica , B.stercoris , B.faecis , B.coccoides ), B.glucerasea , B.hansenii , B.luti , Blau Use of a composition of bacterial strains of the species B. schinkii or B. wexlerae for the preparation of a preparation for the treatment or prevention of diarrhea and/or constipation in an individual , wherein the bacterial strain can convert H ₂ /CO ₂ into acetate.

A use of a composition comprising a bacterial strain having a 16s rRNA sequence at least 97% identical to SEQ ID NO:5 for preparing a preparation for treating or preventing diarrhea and/or constipation in an individual.

The use according to claim 1 or 2, wherein the diarrhea and/or constipation is related to IBS and/or intestinal inflammatory disease.

The use according to claim 3, wherein the inflammatory disease is an inflammatory disease of the small intestine, colon or rectum.

The use according to claim 1 or 2, wherein the diarrhea and/or constipation is related to IBS, Crohn's disease (Crohn's disease) or ulcerative colitis.

The use according to claim 1 or 2, wherein the preparation is for treating or preventing diarrhea and/or constipation in individuals diagnosed with IBS, Crohn's disease or ulcerative colitis.

The use according to claim 1 or 2, wherein the formulation is for treating diarrhea in an individual, and wherein the individual has diarrhea but not constipation.

The use according to claim 1 or 2, wherein the formulation is used to treat constipation, and wherein the individual suffers from constipation but does not suffer from diarrhoea.

The use according to claim 1 or 2, wherein the individual additionally suffers from abdominal pain and/or flatulence.

The use according to claim 1 or 2, wherein the individual has an increased hydrogen concentration in his breath relative to a healthy individual.

The use according to claim 1 or 2, wherein the treatment or prevention further comprises reducing the hydrogen concentration in the individual's breath.

The use according to claim 1 or 2, wherein the treatment or prevention further comprises monitoring the hydrogen concentration in the breath of the individual during and/or after the treatment or prevention and thereby evaluating the possible effectiveness of the treatment or prevention.

A species of Blautia hydrogenotrophica , B.stercoris , B.faecis , B. coccoides ), B.glucerasea , B.hansenii , B.luti , Blau Use of a composition of bacteria strains of B. schinkii or B. wexlerae species, used for preparation of reducing Enterobacteriaceae in the gastrointestinal tract when treating or preventing diarrhea Enterobacteriaceae ), wherein the bacterial strain can convert H ₂ /CO ₂ to acetate.

A species of Blautia hydrogenotrophica , B.stercoris , B.faecis , B.coccoides ), B.glucerasea , B.hansenii , B.luti , Blau Use of a composition of bacterial strains of B.schinkii or B.wexlerae species for the preparation of preparations for the treatment or prevention of diarrhea associated with Enterobacteriaceae infections , wherein the bacterial strain can convert H ₂ /CO ₂ to acetate.

Use of a composition comprising a bacterial strain having a 16s at least 97% identical to SEQ ID NO: 5 for the preparation of a preparation for reducing the concentration of Enterobacteriaceae in the gastrointestinal tract when treating or preventing diarrhea rRNA sequence.

A use of a composition comprising a bacterial strain for preparing a preparation for treating or preventing diarrhea associated with Enterobacteriaceae infection, the bacterial strain having a 16s rRNA sequence at least 97% identical to SEQ ID NO:5.

The use according to any one of claims 13 to 16, wherein the Enterobacteriaceae is Escherichia coli ( E. coli ).

The use according to any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain is a hydrogenotrophic Blautia hydrogenotrophica ( Blautia hydrogenotrophica ).

The use according to claim 1 or 2 and any one of 13 to 16, wherein the bacterial strain is Blautia stercoris .

As the use of any one of claim 1 or 2 and 13 to 16, wherein the bacterial strain is Blautia wexlerae .

As the purposes of any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain has at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.

As the use of any one of claim 1 or 2 and 13 to 16, wherein the bacterial strain has a 16s rRNA sequence that is at least 98%, 99%, 99.5% or 99.9% consistent with SEQ ID NO: 5 or has a SEQ ID NO: 16s rRNA sequence of 5.

As the purposes of claim 1 or 2 and any one of 13 to 16, wherein the bacterial strain has at least 95%, 96%, 97%, 98%, 99% of the 16s rRNA sequence of the bacterial strain of Blautia faecalis %, 99.5% or 99.9% identical 16s rRNA sequence.

As the purposes of claim 1 or 2 and any one of 13 to 16, wherein the bacterial strain has at least 95%, 96%, 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain is a hydrogenotrophic Blautia species, and the individual is diagnosed with IBS.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain is the species of Blautia faecalis and the individual is diagnosed with IBS.

The use according to any one of claims 1 to or 2 and 13 to 16, wherein the bacterial strain is a species of Brautia weiklarii and the individual is diagnosed with IBS.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the composition is administered orally.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the composition comprises one or more pharmaceutically acceptable excipients or carriers.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain is freeze-dried.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the bacterial strain is a live bacterium.

The use of any one of claims 1 or 2 and 13 to 16, wherein the composition comprises: (a) hydrogenotrophic Blautia hydrogenotrophica , B. stercoris ), B. faecis , B. coccoides , B. glucerasea , B. hansen-Broutia ( B.hansenii ), B.luti , B.schinkii or B.wexlerae species A bacterial strain, wherein the bacterial strain can convert _H2 / _CO2 to acetate, or (b) a single bacterial strain having a 16S rRNA sequence at least 97% identical to SEQ ID NO:5.

The use according to claim 1 or 2 and any one of 13 to 16, which comprises (a) hydrogenotrophic Blautia ( Blautia hydrogenotrophica ), Blautia faecalis as part of a microbial consortium ( B.stercoris ), B. faecis ( B.faecis ), B.coccoides ( B.coccoides ), B.glucerasea ( B.glucerasea ), Hansen-Bu B. hansenii , B. luti , B. schinkii , or B. wexlerae A strain of bacterial species, wherein the strain can convert H ₂ /CO ₂ to acetate, or (b) a 16S rRNA sequence having at least 97% identity to SEQ ID NO:5 as part of a microbial consortium.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the preparation is a food.

The use according to any one of claims 1 or 2 and 13 to 16, wherein the preparation is a vaccine.